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The compound 2-methyl-3-phenyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide 
(NSC 108406) was identified as an HIV-1 reverse transcriptase inhibitor by the National 
Cancer Institute. Using this lead, the Baker group has developed a series of analogues 
with various groups at the 3-position that show a spectrum of biological activities. In the 
end, the substituents used could not compare to the biological activity of the inhibitor 
efavirenz (Sustiva® [trademark]), and so it was decided to synthesize sultams with 
alkylethynyl substituents at the 3-position of the sultams in an attempt to mimic the 
activity of efavirenz.  
Previous research analyzed the proposed novel sultams in the modeling program 
FlexiDock contained in the SYBYL package. The FlexiDock modeling performed by 
Riyam Kafri gave evidence for unique binding of the proposed sultams in both wild type 
and Y181C reverse transcriptase. Another in silico method applied to the novel sultams 
was the CoMFA analysis, which looks at the similarities between common compounds 
with known biological activities and uses this information to calculate predicted activities 
for untested compounds.  
Synthesis of the novel ethynyl sultams is achieved by reacting the desired 
lithiated alkylethynyl reagent with 3-chloro-1,2-benzoisothiazole 1,1-dioxide,  pseudo-
saccharin chloride. Methods were designed to yield either the mono-alkylated or the bis-
alkylated products. Various methods for reducing the mono-substituted compounds 
were applied to attempt to achieve the desired S enantiomer. Other methods resulted in 
the production of a racemic mixture of the reduced compounds. The reduced mono- 
 vii 
sultams or the bisalkylated sultams are then methylated to yield the desired final 
product.  
An aryl sultam was also synthesized in a similar method employed by Baker and 
co-workers by reacting saccharin with two equivalents of a Grignard reagent of 3-
bromostyrene. The compound was reduced with the catalyst (R)-Cp*RhCl[(1S,2S)-p-
TsNCH(C6H5)CH(C6H5)NH2] [(R)-pentalmethylcyclopentadienylrhodium chloride-
(1S,2S)-p-toluenesulfonyl-1,2-diphenylethylenediamine] and alkylated with base and 
iodomethane. The vinyl group was reacted in a modified SimmonsSmith fashion to 
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A. AIDS and HIV—The Beginning 
The human immunodeficiency virus, or HIV, is a virus that is an ongoing menace 
to mankind, with several million people either being HIV positive or living with AIDS 
(acquired immunodeficiency syndrome), the full-blown disease that it produces. Since 
HIV was first reported in 1981, it has become a pandemic, and approximately 34 million 
people in the world were living while infected with HIV, while there were 1,700,000 
deaths from AIDS in 2011 alone.1 Of the 34 million plus living with HIV in the world in 
2012, approximately 9.7 million people were receiving antiretroviral therapy in the lower- 
or middle-income countries.1 
When the world became knowledgeable of HIV and AIDS, people believed it 
targeted specific groups of people. Since then, it has been determined that HIV is a 
virus with no discrimination and the ability to infect anyone. HIV is predominately 
transmitted through sexual acts, but can also be transmitted through other methods 
such as contaminated blood transfusions and the sharing of used narcotic needles.1 
HIV may not have been discovered as the causative agent of AIDS as early as it 
was if not for the work by Robert Gallo and co-workers in the 1970s at the National 
Cancer Institute, NCI, with the Human T-Cell Leukemia Virus Type 1 (HTLV-1) and its 
discovery as a retrovirus that affects humans.2, 3 
In June of 1981, the Center for Disease Control (CDC) reported in the Morbidity 
and Mortality Weekly Report of cases of five men with a rare Pneumocystis pneumonia. 
The pneumonia was reported to the CDC by Dr. Michael Gottlieb and colleagues who 
had noticed the infection in several homosexual men.4 What made the pneumonia so 
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unique was that the patients had a lack of CD4 T-cells, helper T-cells, preventing the 
body from fighting the infection. It was found that by the time the CDC released the 
report, already 250,000 Americans were infected with the disease, which came to be 
known as AIDS.4 With the first discoveries in the United States (U.S.) being reported on 
homosexual men, the disease began to be known as “the gay disease” and having ties 
with the homosexual lifestyle. However, in New York in the same year, Dr. Gerald 
Friedland and Dr. Arye Rubenstein began seeing the disease in non-gay men in 
injection drug users, and in some cases symptoms in their children.4 After reading the 
article by the CDC, two European doctors reported seeing similar cases in their 
patients: primarily heterosexual, with the most notable cases including heterosexual 
women in Belgium originally from central Africa.4 
Further support arose against the idea of AIDS being a homosexual disease 
when Dr. Margaret Fischl reported cases to the CDC in 1982 of non-homosexual male 
and female Haitians having both Pneumocystis pneumonia and Kaposi’s sarcoma. 
However, Dr. Fischl reports the CDC initially did not believe her findings.4 
The first signs of AIDS being a viral related situation arose when three 
heterosexual men with hemophilia developed symptoms of Pneumocystis pneumonia. 
The significance of this comes from the treatment of hemophiliacs with plasma from 
donors that is processed through a filtration system that only a virus is small enough to 
slip through.4 Another case was found in a 20-month-old infant who had received 
several blood transfusions that developed immunosuppressant symptoms. It was 
discovered that one out of the nineteen donors of blood for the child had already passed 
away from AIDS.4 
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With more and more cases giving evidence to AIDS being caused by a virus, 
researchers began an investigation to find the cause of the newly discovered disease. 
Gallo began to claim that the source of AIDS could be a retrovirus like HTLV-1. His 
initial tests showed patients diagnosed with AIDS as having positive test results for a 
retrovirus. It was found later that these patients also had HTLV-1, but at the time Gallo’s 
team was convinced that they had discovered a new retrovirus responsible for the 
disease, AIDS, and worked to find out more about the retrovirus.5 Gallo goes on to state 
in a review from 2004 that it was difficult declaring HIV as the causative agent of AIDS 
because AIDS has been known to show signs of infection typically after years since the 
actual date of infection, followed by the fact that once AIDS was shown to be present, a 
patient already had numerous other infections that could have been confused as the 
causative agent.3 
After Gallo’s group released information regarding a new retrovirus as the 
causative agent in AIDS, a group at the Pasteur Institute in Paris led by Luc Montagnier 
were prompted to lead studies on the new retrovirus.5 The group obtained the biopsy of 
a lymph node of a homosexual patient with multiple lymphadenopathies and symptoms 
that had become known to be early signs of AIDS. The initial studies found that a 
retrovirus was present in the lymph node biopsy with ionic requirements of a viral 
reverse transcriptase related to that of HTLV, but it had viral core proteins not 
immunologically related to the p24 and p19 proteins of sub-group 1 of HTLV.6 Further 
studies included comparing the proteins of the newly discovered retrovirus with proteins 
of other HTLV species isolated from various cases, which resulted in seeing a relation 
between various HTLV species and the new retrovirus, but with some very clear 
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differences. With personal communication with Gallo, Montagnier reported that studies 
show the nucleic acid sequences of the new virus have less than 10% homology with 
that of other HTLV isolates.6 Even with this new information, Montagnier’s group did not 
link the new retrovirus to AIDS at the time because the patient was not diagnosed with 
“frank” AIDS.5 
Montagnier’s group later went on to collect several isolates of a retrovirus from 
AIDS-positive patients and labeled them as IDAV-1 and -2 for immune deficiency 
associated virus. However, before Montagnier published information involving IDAV-1 
and -2 in 1984, Gallo’s group isolated viruses that did not display immunological cross-
reactions with HTLVs, and they began to have two isolates continue to grow through 
cell-line cultures.5 Gallo et al. would use the experiments involved in the cell-line 
cultures to develop a blood test that was later used to confirm the presence of the newly 
discovered virus, termed HTVL-III, in 48 different patients.5, 7, 8 From their collection of 
evidence through their studies, Gallo’s group was able to determine that HTVL-1, which 
was later termed HIV, was the single cause of the disease, AIDS. 
With the development of the first conclusive blood test for HIV from Gallo et al., 
donated blood for transfusions could be tested for infection to prevent the further spread 
of the virus. Furthermore, with the development of the continuous cell-line cultures, 
testing for anti-HIV drugs could be performed such as with azidothymidine (3’-azido-3’-
deoxythymidine, AZT), the first moderately successful anti-HIV drug.5, 9 
B. Possible Origins of HIV 
 The primate lentivirus group consists of the two strands of HIV and various 
simian immunodeficiency viruses (SIV). Among the primate lentivirus group are five 
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different lineages, with HIV-1 and HIV-2 coming from two different lines.10 Since 
documentation of the two serotypes of HIV, it has been found that HIV-1 can be 
accounted for a majority of infections around the world.11 Viral cluster experiments show 
that HIV-1 clusters with that of SIVCPZ, chimpanzee SIV, suggesting that the source of 
HIV-1 comes from the chimpanzee subspecies Pan troglodyte troglodytes with evidence 
pointing to wild species of P. t. troglodytes in southern Cameroon being the likely 
original source.10, 12 This leads to theories of the origin of HIV-1 and 2 as being in the 
area of West Africa. 
One counter theory from Carel Mulder argues that the differences between HIV 1 
and 2 sequences from that of SIV are so distinct that the origin could not have occurred 
recently.13 Instead, Mulder argues that HIV has been around for much longer and 
evolving with primates along the way. 
Studies of the origin of HIV-1 have been estimated to date back as far as the 
1920s with the use of molecular clocks, and samples obtained in 1960 has corroborated 
this time scale through the analysis of the diversified group M strains of HIV-1.14 It was 
also found in the study that a common ancestor of HIV-1, HIV-2, and SIVAGM existed 
about 150 years ago instead of the millions of years mentioned by Mulder.10 The use of 
the molecular clock study investigates the viral sequences and notes the different 
mutations through time, allowing a rate of change to be estimated. However, there is the 





C. The Lifecycle of HIV 
1. Overview 
 There are several methods of treatment for HIV as of now with up to 20 different 
clinical pharmaceuticals on the market, but to understand how these methods of 
treatment work, HIV’s life cycle of infection to reproduction should be discussed.  The 
infection begins with the virus attaching to and becoming a parasite on a target cell 
(Figure 1).  The virus binds via its glycoprotein-120 (gp120) to the CD4 receptors on T-
lymphocytes, macrophages, monocytes, and/or dendritic cells.  From here, the gp120 
that bonded to the CD4 receptors binds to one of the chemokine receptors, CXCR4 or 
CRC5, which leads to the insertion and uncoating of the virus and insertion of its RNA 
and key enzymes for reverse transcription and nucleic acid integration.5  Once inside 
the cell, the viral RNA goes through reverse transcription with the HIV enzyme, reverse 
transcriptase, to generate a complimentary DNA strand of the viral RNA.  Next a 
double-stranded HIVDNA is then produced and then proceeds to integrate into the 
cellular genome through the enzyme HIV integrase.  The infected cell then becomes 
activated, resulting in the production of messenger RNA encoding for viral proteins, and 
then, within approximately 2.5 days of infection, virus particles begin budding out of the 
cell.  Once out of the cell, viral polyproteins are cleaved by HIV protease, which results 









2. Viral Entry—Fusion 
 For the virus to infect a host cell, it must first gain entry into the cell, and this 
begins with a process known as attachment followed by fusion. The virus first begins by 
the cleavage of glycoprotein 160 (gp160) into glycoprotein 120  (gp120) and gp41.16 
This step is followed by the binding of the subunit (gp120) of the viral envelope to the 
CD4 receptor site on the host cell (T-lymphocyte) wall.17 Once the gp120CD4 
interaction has occurred, the virus proceeds next to binding to either a CCR5 (HIV 
strains that infect macrophages, M-tropic or R5 strains) or CXCR4 (strains that infect T-
cells, T-tropic or X4 strains) chemokine co-receptor.18 Following the gp120 and 
coreceptor binding, the gp41 subunit is altered to prepare itself for the formation of the 
pre-fusion intermediate designated the extended coiled-coil.17 Before the coiled-coil 
inserts into the target cell membrane, a six-helix bundle, nicknamed the hairpin 
conformation, forms from what is known as the C- and the N-terminal heptad repeats of 
gp41 coming into a tight association together as the fusion peptide and the 
transmembrane domain of gp41 come into apposition bringing the two membranes, viral 
and target, close to each other allowing the merger to proceed.17 This six-helix bundle 
forms a fusion pore that allows the release of the viral capsid into the cytosol of the 
target cell.17 
3. Reverse Transcription 
 The reverse transcriptase enzymes of retroviruses perform up to three enzymatic 
activities. These enzymatic activities include: an RNA-dependent DNA polymerase 
(RDDP), ribonuclease H (RNase H), and a DNA-dependent DNA polymerase (DDDP). 
The enzymes execute the steps in the order of copying a plus-strand RNA genome to 
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produce a minus strand of DNA (RDDP), removal of the plus-strand RNA template 
(RNase H), and the synthesis of a plus-strand of DNA with the minus-strand of DNA 
acting as a template (DDDP).19 
 The RT of HIV is a heterodimer consisting of a large p66 subunit (66-kDa) 560 
amino acids in length and a small p51 subunit (51-kDa) 440 amino acids in length with 
common N termini.19, 20 Both p66 and p51 contain the polymerase domain of RT (RDDP 
and DDDP), while a C-terminal fragment that is removed from the p66 subunit is 
involved with the RNase H domain of RT.19 In the activity of the two subunits, it has 
been found as homodimers, they remain active, but as a monomer, both subunits 
become inactive.21 Furthermore, altering the p51 subunit by mutation shows little effect 
on the activity, while mutating the p66 subunit in some way causes the heterodimer to 
be inactive.22 
 The structure of HIV-1 RT, as seen in an X-ray crystal structure, shows that 
overall the enzyme is asymmetric, but both p66 and p51 contain subdomains labeled as 
“finger,” “palm,” “thumb,” and “connection.” The p66 subunit is positioned such that the 
finger, palm, and thumb domains are open in a sense of forming a cleft, termed a “hand” 
shown to be the active site of the enzyme (Figure 2). The p51 subunit and the p66 are 
joined at the connection domain, which is rotated such as that the palm of p51 is hidden 
within the enzyme.19 This shape supports the activity discussed previously of it 
appearing the p66 subunit being largely responsible for reverse transcription to proceed.  
Both the polymerase and the RNAse H of RT reside in the p66 subunit. The two 
active sites are located as such that a (+)-strand RNA template (tRNALys) enters 
“through” the fingers and thumb of RT where it attaches to the 18 nucleotide primer 
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binding site (PBS).23-25 The RNA strand passes through the RDDP enzyme to be 
transcribed into a (-)-strand of DNA starting from the 5’ end of the (+)-strand RNA. From 
here the combined RNA/DNA strand is fed into RNAse H, which removes the RNA 
strand so that the (-)-DNA strand could be used as a template to form a complete 
double stranded helix of viral DNA as it is passed through the DDDP. It has been 
theorized that the RDDP and the DDDP are one in the same.19 After the DNA replication 
process has completed, the integration process begins. 
Since its discovery, there have been crystal structures analyzed and 
characterized of RT as it is bound with an inhibitor, a double-stranded DNA, and a 
polypurine RNA:DNA double strand and unbounded RT. Through each structure, it was 
seen the flexibility of the thumb and fingers of the RT active site.26-28 The shape of the 
RT enzyme is altered at the thumb position when RT is either bound or unbound. When 
RT is unbound, the thumb is placed in an upright position, residing in close proximity of 
the finger subdomains.29 It was found that there are two small and weak interactions 
between the thumb and fingers at the Arg78 amino acid of the fingers with the main 
chain of the thumb and a nonpolar interaction between Phe61 in the fingers and Leu289 
of the thumb. These interactions allow for the mobility of the thumb to be flexible and 
free because of their weak interactions. The shape of the active site with the presence 
of either a double-stranded DNA or the RNA:DNA double strand showed a similar 
shape with the finger and palm subdomains interacting heavily with the substrates 
present in the cavity.27, 28  
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The ability for the catalytic site to be so flexible has allowed for RT to be a viable 
target for inhibition (Figure 2). (The mechanism for NNRTIs shall be discussed in detail 








Figure 2. Reverse transcriptase with efavirenz (green) in binding pocket 
of palm. (pdb code 1ikw).  
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 4. Integration 
 Integration is an important step in the viral replication cycle, in that it is 
responsible for ensuring a stable relationship between the viral DNA from reverse 
transcription and that of the hostcell chromosome.19 Before integration begins, a pre-
integration complex forms, which isolates show the complex involving the linear viral 
DNA, reverse transcriptase, nucleocapsid integrase, and two cellular proteins (high-
mobility-group, HMB-I(Y), and barrier-to-autointegration factor, BAF). Once formed, the 
pre-integration complex of HIV-1 enters the nucleus through the nuclear pore, where it 
then catalyzes integration.30 
 Integrase is responsible for cleaving the 3’-end groups of the viral DNA to expose 
hydroxyl groups at the 3’-ends so that host DNA can connect to the viral DNA. Once 
connected, the exposed viral DNA is inserted into the cellular DNA of the host, and this 
action can occur at any location on the host cellular DNA.31  
 After integration is complete, a viral polyprotein is synthesized by use of cellular 
machinery within the host cell.32 Once synthesized, the viral polyprotein is subject to 
cleavage by the enzyme HIV protease. 
5. Protease Interaction 
 As previously stated, the next step in the replication process is cleaving of the 
polyproteins in the protease (PR) enzyme to form mature viral particles. The HIV PR is 
composed of 99 amino acids, and belongs to the aspartyl protease class. All retroviral 
PRs, especially those of HIV, are monomers that contain a single conserved active-site 
triplet, Asp-Thr/Ser-Gly, and upon activation the PRs become a dimer.19 As stated, the 
protease is responsible for cleaving the polyproteins, but so far no distinctive primary 
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sequence of amino acids has been found within a substrate polyprotein at the cleavage 
sites. Some common characteristics to be found are that the area around the cleavage 
sites are hydrophobic sequences, and a strongly conserved feature is at the N-terminal 
side of the cleaved bond.33 The protease of HIV is an attractive target for inhibition, 
because each kind of retrovirus has to rely on its own PR for maturation to occur.34 
D. Methods of Treatment: Chemotherapy  
 These processes necessary for the reproduction of HIV provide several points of 
pharmaceutical intervention, and several treatments have been developed involving 
inhibitors for the different processes. However, HIV has a high rate of mutation through 
its replication, with reverse transcriptase having the highest affinity for error. With this 
being the case, when a patient is treated with anti-virals that are active against wild-type 
HIV, the mutant strains that develop with a resistance to the inhibitor proceed on to 
replicate further making treatment difficult. Nevertheless, given the fact that an anti-HIV 
vaccine has eluded researchers for more than 30 years, and even today there seems to 
be little hope for an effective vaccine,35, 36 chemotherapy is in reality the only method for 
combating the virus. 
As previously discussed, the method of HIV reproduction is the act of the virus 
attaching to the cell at the CD4 receptor, binding to a co-receptor, fusion of the cell 
membrane, reverse transcription, integration, and the synthesis of new viral particles 
from the cleavage of polyproteins by protease. Each step in the replication process has 
been studied with the intent of designing inhibitors for treatment in anti-HIV therapy, with 
some inhibitors already on the market for patient use. 
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1. Virus Attachment and Fusion Inhibitors 
i. CD4 Receptor Inhibitors 
As already discussed, the initial action of viral replication is the attachment to the 
CD4 receptor on the host cell wall. There are currently no pharmaceutically compounds 
approved on the market for inhibiting cellular CD4 receptors; however, there are classes 
of compounds showing inhibitory activity in studies. A series of analogues of 
cyclotriazadisulfoamide (Figure 3) are being investigated for preventing the viral 
attachment to the CD4 receptor.37, 38 The inhibitors do so by down-modulating the CD4 
receptor expression on cell surfaces without affecting other receptors, CXCR4 and 
CCR5.39, 40 CADA has been found to be able to work alongside with other anti-HIV 
inhibitors such as NNRTIs, NRTIS, and protease inhibitors, which allows it to be added 







ii. gp120 and gp41 Inhibition 
A series of inhibitors has been identified for activity in preventing the gp120 from 
attaching to the CD4 receptor. It has been assumed that whether the inhibitor is 
naturally occurring or synthesized it acts by shielding off the positively charged sites in 
the V3 loop of the viral envelope of gp120, therefore preventing viral attachment.18 
Among these is a group of plant lectins from Galanthus nivalis (GNA) and Hippeastrum 
hybrid (HHA) that are mannose specific. The lectins have low toxicity and are 
considered to act as topical microbicides.42  One microbicide being investigated is the 
protein cyanovirin-N isolated from the cyanobacterium Nostoc ellipsosporum.43 Another 
potential highly active lectin isolated from red algae, Griffithsia, being studied is 
griffinsin.44, 45 Both cyanovirin-N and griffithsin bind to the gp120 and inhibit the binding 
to the CD4 receptor both dependently and independently. Another potential gp120 
inhibitor for viral attachment to CD4 is BMS-378806 [(4-benzoyl-1-[4-methoxy-1H-
pyrrol[2,3-b]pyridine-3-yl]oxyacetyl)-2-(R)-methylpiperazine]. Unlike the two lectins, 
BMS-378806 has shown to be only active with dependent binding with CD4; this means 
it only affects the CD4—gp120 interaction.46, 47 The three gp120 inhibitors discussed are 
shown in Figure 4. 
Another type of viral attachment inhibitors is that of the gp41 class of inhibitors. 
Most notable of these is enfuvirtide, as it has been FDA approved for HIV treatment as 
of March 2003. Enfuvirtide (Figure 5) is a linear, 36 amino acid synthetic peptide 
resembling part of the HR2 region of gp41 causing it to act as a competitive inhibitor 
against HR1 binding.48 A series of smaller molecule peptidic fusion inhibitors (Figure 5) 
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iii. Co-receptor Inhibitors 
As previously discussed, after the viral gp120 has been bound to the CD4 
receptor, the virus then attaches to either of two co-receptors, CCR5 or CXCR4. The 
class of co-receptor inhibitors has included proteins, small molecules, and antibodies. 
The inhibitors interact with either the CCR5 or CXCR4 receptors or the viral envelope in 
order to prevent the interaction of the co-receptor with the viral envelope. Among the 
inhibitors developed, the first one was TAK 779 as an inhibitor of the CCR5 co-receptor 
(Figure 6). Compound SCH351125 has shown activity, but is not yet in clinical trials. 
The inhibitor maraviroc was approved by the FDA in August of 2007 and is currently 
part of treatment methods for co-receptor inhibition of HIV. Vicriviroc is currently in 





Figure 6. Inhibitors affecting CXCR4 and CCR5. 
 
2. Integrase Inhibitors 
Inhibitors for integration are relatively new for HIV treatment. The compound 
raltegravir (Figure 7) was approved by the FDA in October of 2007. Raltegravir acts by 
inhibiting the final step of the integration process, blocking the strand transfer of viral 
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DNA to the host cell DNA.18 Another integrase inhibitor is elvitegravir, which was 




3. Protease Inhibitors 
Unlike the previous groups of inhibitors, protease inhibitors are a larger class of 
FDA-approved compounds. The protease inhibitors act as competitive inhibitors against 
the protease enzyme in its action to cleave viral polyproteins. The inhibitors are 
substrates of CYP3A4, and they either act by inhibiting or inducing specific CYP 
isoenzymes at varying degrees.18 The earliest FDA-approved protease inhibitors were 
indinavir and saquinavir (Figure 8) approved in December of 1995, and most recently 




4. Reverse Transcriptase Inhibitors 
The process of reverse transcription has been highly investigated for inhibition 
studies of the RT enzyme.9 Reverse transcriptase has been found to have three types 
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of inhibitors: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse 
transcriptase inhibitors (NtRTIs), and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs). 
NRTIs and NtRTIs are competitive inhibitors that require activation to their 
triphosphate forms by the host cell kinase enzymes.18 Once activated, the NRTIs bind to 
reverse transcriptase at the active site and cause chain-termination of the viral DNA by 
mutating reverse transcriptase.6, 50 These inhibitors are also able to be integrated into 
the viral DNA being synthesized in RT causing the chain elongation to be terminated 
because of the lack of a 3-OH preventing the formation of phosphodiester linkages.18, 51 
The NRTIs have shown toxicity because of the partial inhibition  of human DNA 
polymerase, but the level of toxicity is dependent on each NRTI.18, 51 
Figure 9 shows five of the NRTIs and an NtRTI on the market as of 2012. The 
first compound in the figure, AZT, was the first anti-HIV drug approved by the FDA for 
treatment.52 After the discovery of AZT, various NRTIs were synthesized by either 
adjusting the nucleobase, the attached sugar moiety, or both. This method lead to the 
design and synthesis of emtricitabine, as one of the more potent NRTIs on the market, 





Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are highly specific, 
noncompetitive inhibitors and require no activation for them to bind to RT. NNRTIs are 
able to be structurally diverse in their make-up, while most share a butterfly wing shape 
when bound in the NNIBP.53 NNRTIs have been shown to bind to a site distinct from the 
NRTIs on reverse transcriptase known as the non-nucleoside inhibitor binding pocket 
(NNIBP) (to be discussed in more detail in section E).5, 50 The NNRTI class have shown 
to bind specifically to the RT of HIV-1 and not of HIV-2 or other retroviruses’ RT.54 The 
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reason for inactivity with HIV-2 is due to the residues making up the allosteric binding 
pocket of HIV-2 compared to HIV-1. The pocket of HIV-1 consists of hydrophobic 
aromatic residues, while the wild type HIV-2 pocket has primarily aliphatic residues.55 
The NNRTIs have been shown to have effective concentration (EC50) as inhibitors at 
concentrations 50% lower than that of the cytotoxic concentration (CC50).
54 
 The first class of NNRTIs to be discovered belong to the TIBO, 
tetrahydroimidazo[4,5,1-jkj][1,4]benzodiazepine-2(1H)-one and -thione, group. The 
studies involved the screening of around 600 molecules led to the TIBO ring system 
with a ketone, R14458, and after alterations to the compound by changing the ketone to 
the thione, the allyl group to 3-methyl-2-butenyl, and adding a chloro group to the 
aromatic ring produced R82913 with IC50 1.5 nm, a potency 41,000-fold greater than 
R14458.56, 57 The TIBO group were then used in the investigation of the mechanism of 
inhibition of RT to better understand the act of inhibition for further development of 
compounds.58 
 Although the TIBO group had been the first class to be designated as NNRTIs, 
they weren’t the first NNRTIs discovered. The HEPT, 1-[(2-hydroxyethoxy)methyl]-6-
(phenylsulfanyl)thymine) compounds had first been discovered in 1989 by Baba et al.; 
however, they were first described as NRTIs.58, 59 Kinetic studies were performed with 
HEPT compounds, and it was eventually found that they did not compete with the 
thymidine triphosphate during the polymerization step. Furthermore, the triphosphate of 
HEPT was a weaker inhibitor than that of HEPT itself. It was not until the investigation of 
the mechanism of inhibition of the TIBO class that it was suggested that HEPT could 
also be an NNRTI.56 
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 Since the discovery of TIBO and HEPT as NNRTIs, they have been discontinued 
in clinical use, but there have since been several generations of new NNRTIs.60 Among 
the first generation of NNRTIs are the compounds nevirapine and efavirenz. Since their 
approval by the FDA, HIV-1 has resulted in mutant strains of RT that have shown 
resilience to the first generation. The second generation of NNRTIs, for example, 
etravirine or rilpivirine, were designed to combat the effect of the Y181C or K103N 
mutation with emphasis on interactions with the conserved residues of RT like W229.52 
Compounds such as efavirenz inhibit the RT process at concentrations in the 
nanomolar range. Structures of the mentioned NNRTIs can be seen in Figure 10. 
 As mentioned earlier, once bound in the NNIBP, the inhibitors take on a folded 
“butterfly” wing-like shape. The later inhibitors such as nevirapine and efavirenz were 
designed to abate the formation of this shape.61 To better adapt the butterfly wing 
shape, the inhibitors must meet three criteria: two -systems, a body or bridge that 
connects the two -systems, typically made up of a thiocarbonyl, a carbonyl, or a 
sulfonyl moiety, and a methyl or some other alkyl group at the meta-position of the 
extended -system. In the end, the NNRTIs that meet this criteria form a rigid 
structure.53 
 Some NNRTIs do not exhibit the butterfly shape or it isn’t as obvious. In 
opaviraline and UC-781, the top wing (the -system that interacts with the residues Tyr 
181, Tyr 188, and Trp229) is decreased in size or even nearly absent compared to other 





E. The Non-Nucleoside Reverse Transcriptase Inhibitor Binding Pocket  
The NNIBP (Figure 11), as discussed, is the site for attachment of NNRTIs. It is 
an allosteric, hydrophobic site that is roughly 15 Å away from the catalytic site of RT and 
is between 620 to 720 Å3 in size.52, 58 The site is located within the palm of the p66 
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subunit of RT. The pocket is comprised of amino acid residues 105110 and 179191 
of the beta-sheets 4, 7, and 8, residues 224241 of the sheets 9, 10, and 11, 
residues preceding the 4, 98104, and the amino acid residues 59, 132, 138, 139, 
141, and 318.54, 58 The pocket mouth contains the two residues Pro225 and Pro236 
which have been theorized as “closing the door” of the pocket once the NNRTI has 
entered.54 Specifically, the roof of the pocket is formed by the aromatic residues Tyr 
181, Tyr 188, and Trp 229, and the walls are made up of Leu 100, Val 106, and Leu 





Figure 11. The non-nucleoside reverse transcriptase inhibitor binding pocket. 
 
Interestingly, crystal studies of RT without a ligand attached found the absence of 
the NNIBP, and it was found only to exist when bound with an inhibitor.26 The formation 
of the pocket results in the induction of a conformational change of the side chains of 
Y181 and Y188 in the direction of the catalytic site, resulting in a related movement of 
the 4-7-8 sheet and three of the amino acid residues at the catalytic cite by 2 Å.62 It 
is theorized the inhibition is caused from this change in the beta-sheets and the catalytic 
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triad. The pocket will typically conform to a similar shape independent of the structure of 
chemically different NNRTIs.58  
 The NNRTIs each have their own unique interaction within the binding pocket, 
but the differences are quite minor from each other. The most important interaction for 
the NNRTIs to exhibit is the  interaction felt with one or more of the residues Tyr 
181, Tyr 188, Trp 229, and/or Tyr 318, with the more interactions occurring the better. 
Another interaction is the electrostatic charges occurring with residues Lys 101, Lys 
103, and Glu 138 with the aromatic wing of an NNRTI. A third interaction to occur with 
ligands and the pocket is the van der Waals interaction that occurs with resiudes Leu 
100, Val 106, Val 179, Tyr 181, Gly 190, Trp 229, Leu 234, and Tyr 318. A potential final 
interaction are hydrogen bonds that occur with the ligand to the main chain peptide 
bonds of Lys 101 and/or Lys 103.54 
F. Mutations Induced by NNRTIs 
 Since the use of NNRTIs began, several mutations arose leading to drug 
resistance of NNRTIs. These mutations differ from those formed from NRTI treatment; 
furthermore, NNRTI induced mutant strains retain sensitivity to NRTI treatment and vice 
versa.63 Unlike NRTI-induced mutations that can occur throughout RT, NNRTI induced 
mutations occur only in the NNIBP.63 Most mutations are as simple as one amino acid 
being changed to another with variability on whether one inhibitor is made inactive or 
not. The first two resistant mutations seen were the K103N (Lys 103  Asn 103) and 
the Y181C (Tyr 181 Cys181) strains, both of which rendered almost all known 
NNRTIs inactive. In some extreme cases, double mutations have occurred. The more 
prevalent double mutations are K103N/Y181C, L100I/K103N, and K101D/K103N.64 
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Table 1 shows a list of possible mutations and the NNRTI that was used in the 
treatment that led to the mutation. 
 A valid question arises, “Since NNRTIs give rise to rapid mutation, are these 
viable inhibitors to develop.” Two schools of thought offer discordant opinions. One is, 
yes, mutations seriously impede these drugs and they should be abandoned. The other 
is, no, we need a succession of ever-more potent NNRTIs to meet the challenge of 
mutant strains. Moreover, NNRTIs seem most effective as components of 3- or 4-way 
cocktail regiments for long-term therapy.65 
 
Table 1. Mutations with resistance to NNRTIs and the NNRTI used in treatment. 
nevirapine (NEV), deliviradine (DLV), and efavirenz (EFV).54 
Amino Acid 
Mutations in RT 
NNRTI used to cause 
mutation 
98-Ala-->Glu NEV 
100-Leu-->Ile NEV, DLV, EFV 
101-Lys-->Glu EFV 






181-Tyr-->Cys/Ile NEV, DLV, EFV 
188-Tyr--
>Cys/His/leu NEV, DLV, EFV 
190-Gly--






G. Sultams: A novel class of NNRTIs 
1. The Discovery of Sultams as NNRTIs  
The initial design of the sultam class of NNRTIs resulted from Gussio et al. 
developing a structure for the NNIBP with an all-atom model from a crystal structure of 
reverse transcriptase complexed with the inhibitor nevirapine.66 The group used the 
known C- coordinates from the crystal structure with only a resolution of 2.9 Å. After a 
series of tests using structural probes based on nevirapine and nevirapine analogs with 
known structureactivity relationships, a reasonably accurate and complete NNIBP was 
developed. From here, new NNRTIs could be analyzed in this more complete binding 
pocket model.66 
 After comparisons of nevirapine analogs, a 3-D QSAR (quantitative 
structureactivity relationship) model was developed. Using the 3-D QSAR and density 
functional theory (DFT), a stereoelectronic pharmacophore was designed to use in 
designing new inhibitors.66 With this newly designed pharmacophore, Gussio and co-
workers at the National Cancer Institute (NCI) conducted a search of its database of 
over 200,000 compounds. After several runs through the database with parameters 
designed to narrow the field each run, a list of 33 potentially active molecules with 26 of 
these being structurally novel molecules. Among the 33 molecules were the compounds 





 Another search through the NCI database produced a few new results of active 
compounds. One compound to come out of this was NSC-108406 (Figure 13). NSC-
108406 showed inhibition activity with an IC50 of 0.5  0.3 M and an EC50 of 1.5  1.0 
M.67 NSC-108406 belongs to a family of compounds known as sultams, which the first 
synthesis of a similar compound was discussed by Hauser and co-workers, and other 
methods were developed by Baker and co-workers, unpublished work, to produce over 






2. The Synthesis of Sultams  
The sultams discussed here are derivatives of isothiazoles with an aromatic ring 
being fused at the C4 and C5 positions with numbering starting with 1 at the sulfur 
atom. The Baker lab developed sultams resembling that of the compound shown in 
Figure 10 with the aromatic ring attached to the isothiazole ring being ring A, Ring B the 
heterocycle, and Ring C another aromatic ring. The initial studies had the nitrogen atom 
being either secondary or tertiary depending on whether R1 was a hydrogen or an alkyl 
group, and with various substituents at either C6 or C7 in ring A. It was later discovered 
that altering groups at C6 or C7 decreased activity, and it was the effect of using various 
substituents at the meta position of Ring C, labeled R2, that enhanced activity. The 





In Scheme 1, the first step is the coupling of a primary amine with a substituted 
benzenesulfonyl chloride to form compound 1-1. When 1-1 is reacted with n-
butyllithium, the hydrogen at the ortho position is lithiated, which reacts with a meta-
substituted benzaldehyde (1-2) to produce 1-3. Upon reaction of 1-3 with a protic acid, 
the racemic final compound 1-4 is formed from the cyclization of 1-3. Initial methods 
used a chiral semi-preparative column on HPLC to separate the enantiomers, where 
they were sent to NCI for biological testing.68, 70 
The original method for synthesizing the sultams was flawed when analogues 
with a halogen as a substituent was desired because of the tendency of alkyllithium to 
perform a lithiumhalogen exchange reaction. To circumvent the production of side 
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products, a new method was developed, Scheme 2. A halogen-substituted ortho-
aminobenzophenone (2-1) was first reacted with HONO to produce a diazonium 
compound, which upon reaction with SO2 in ionic copper produced 2-2. Ammonia was 
used to perform a condensation on 2-2 to produce 2-3, which was then hydrogenated to 
form racemic 2-4. The final step involved the alkylation of the nitrogen to produce 




In the early days of the project other methods were designed, patented, and 
employed in the laboratory as shown in Scheme 3. Compound 3-1, 2,4-
(dimethoxyphenyl)-(4-methoxyphenyl)methylamine was reacted with benzenesulfonyl 
chloride in the presence of a base to form 3-2. After ortho-lithiation of the aromatic ring 
attached to the sulfur, benzaldehyde or substituted benzaldehyde was added to yield a 
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A fourth method was developed to involve a CF3 group at the C3 position in ring 
B, Scheme 4. The method starts with reacting tert-butylamine with benzenesulfonyl 
chloride to yield 4-1. The nitrogen atom in 4-1 is deprotonated with sodium hydride, 
which the negative charge performs an SN2 reaction on iodomethane to form 4-2. 
Compound 4-2 is ortho-lithiated with n-BuLi and then reacted with 2,2,2-trifluoro-1-
phenylethanone to produce 4-3, which is cyclized with sulfuric acid to produce the 




 As it was done with the final compound in Scheme 1, the final compounds in 
Schemes 23 (2-5, 3-5, and 4-4) were purified into the desired enantiomer 
predominately with chiral separation with a Chiralcel OD column on HPLC. Some 
enantiomers were purified with derivitization into the respected diastereomer and then 
separated with liquid chromatography and recrystallization.  
 Initial biological studies showed a decrease in activity of compounds with altered 
substitution on Ring A as directed by models supplied by the NCI team. When these 
diminished activities were realized, the Baker group re-evaluated the model and 
determined that Ring C was the more likely candidate for insertion into the NNIBP of the 
enzyme; hence, modifications were made on this part of the molecule. Since Ring A 
was to only be unsubstituted, the Baker group developed a method of synthesizing 
analogues with various substituents on Ring C starting initially from saccharin. Using 
methods developed by Abramovitch and co-workers, saccharin was reacted with 2 
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equivalents of an aryl magnesium bromide or chloride to yield 5-1.74 Initially, 5-1 was 
reduced with a ruthenium chiral catalyst developed by Noyori et al. to yield the desired 
enantiomer 5-2.75, 76 The nitrogen atom was deprotonated with Cs2CO3 and alkylated 




  As shown in Scheme 5, a chiral TsDPEN-Cp*rhodium chloride catalyst was also 
used in the asymmetric reduction of 5-1 to 5-2. The idea of the use of rhodium came 
from an article in C & E News about the use of rhodium being used to reduce imines to 
amines effectively.77 The Baker group set forth on the synthesis of a chiral rhodium 
catalyst with related ligands to the Noyori catalyst previously used. The rhodium catalyst 
was prepared by reacting pentamethylcyclopentadienylrhodium chloride dimer with 
either (1R,2R)-N-p-toluenesulfonyl)-1,2-diphenylethylenediamine [(1R,2R)-TsDPEN] or 
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[(1S,2S)-TsDPEN] to form the red R,R-catalyst or the S,S-catalyst, respectively.78 As 
one can see in Figure 14, the catalyst has three chiral centers: the two carbons in the 
TsDPEN ligand and the rhodium metal; however, the catalyst will be referred to as 
either R,R or S,S. The catalyst was characterized by single-crystal X-ray diffraction 
analysis of the R,R isomer of the catalyst.78 Experiments were performed with a 5:2 
formic acidtriethylamine azeotrope as the hydrogen source to test the viability of the 
catalyst on various imines, differing solvents, time, and different substrate-to-catalyst 
ratios. It was found the catalyst resulted in better enantioselectivity in polar solvents, 
and the preferred solvent of choice was dry dichloromethane. In some cases, the 
catalyst performed the reduction in as little as 10 minutes at room temperature, but it 
was safe to run the reaction up to say 30 minutes. The catalyst performed well with a 
S:C ratio of 200:1 compared to the Noyori catalyst with Ru of 100:1. It was found that in 
most cases it could be said that the R,R catalyst resulted in the S enantiomer of the 
product, and vice versa, but this result was dependent on the substitution on the imine 
substrate. In a case of 3-phenyl-1,2-benzisothiazole 1,1-dioxde, the resulting product 
was the S enantiomer with the use of the R,R catalyst, while  3-(2-chlorophenyl)-1,2-
benzisothiazole 1,1-dioxide with the same catalyst would result in the R enantiomer 





 The catalyst was found to be quite stable at room temperature, and it even was 
found to be effective at cold or warm temperatures with little effect on the 
enantioselectivity.  
 With the new method involving saccharin as the starting material, and the highly 
effective rhodium catalyst, the possibility of synthesizing more and new sultams with 
defined stereochemistry could be investigated for potential anti-HIV activity. 
3. The First Sultams with Enhanced Activities 
 As previously mentioned, it was found that the most active compounds involved 
substituents on the meta position of the C ring. Among the substituents synthesized and 
tested, four stood out as having the highest inhibition activity (Figure 15). All four 
compounds were synthesized as is shown in Scheme 5. The activities of the 
compounds can be viewed in Table 5, but the most active of the four is the compound 
(S)-3-(3-methylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxde with an 
EC50 of 0.037 M (work unpublished).
72 However, the compound Efavirenz from 
Sustiva® showed higher activity, and the Baker group sought out a way to make a 





H. FlexiDock Modeling 
 To begin the process to look for similiarly active sultams to efavirenz, Dr. Kafri 
used the FlexiDock modeling tool of the program SYBYL as an investigative resource 
for potentially interesting binding in the NNIBP of HIV RT with new compounds.79 Kafri 
prepared each novel compound designed for the project in the SYBYL modeling 
program (Figure 16). Each compound was drawn and minimized with the Tripos Force 
Field and GasteigerHückel charges. Each compound was docked into the NNIBP of 
the modeled RT crystal structure with the inhibitor efavirenz by superimposing the 
sultam on top of efavirenz. After preparing the FlexiDock file to process the sultam’s 
effect in the pocket, the potential hydrogen bonds, the hydrogen bond angles, and 
distances of the hydrogen bonds in the pocket to the sultam were observed. In Kafri’s 
findings, the sultams showed unique binding in the pocket that had some similarities 




 Table 2 shows the comparison of efavirenz to the mono-alkylated sultams: 
cyclopropylethynyl, cyclobutylethynyl and tert-butylethynyl, within the NNIBP as studied 
by Kafri. In binding studies, it is generally expected that a strong hydrophobic interaction 
should show a distance between residue and ligand being less than 4 Å, a moderate 
interaction being 45 Å, and anything larger than 5 Å is considered a weak interaction.80 
With this knowledge, the three mono-alkylated sultams have some form of interaction 
within the binding pocket with the interaction with Tyr 183 being the weakest at roughly 
7.5 Å with all four inhibitors. The cyclopropyl sultam shows the closest similarity with 
efavirenz interaction with Lys 101 at 2.10 Å compared to efavirenz 2.06 Å, but both the 
cyclobutyl- and tert-butylethynyl sultams still showed at least a moderate or strong 
interaction respectively to Lys 101. The substituents at the end of each ethynyl group: 
cyclopropyl, cyclobutyl, and tert-butyl, all shared similar distances from Tyr 188 and Trp 
229 with almost stronger interactions occurring throughout the sultam group. 







Table 2. Distance of NNIBP residues to ligands and angles of 
hydrogen bonds if present with wt RT (wt RT). (CP = 
cyclopropyl; Ar = aromatic ring; CB = cyclobutyl; t-Bu = tert-
butyl.79 
    
wt RT Efavirenz 
Cyclopropylethynyl 







H-bond   
Distance 
(Å) Angle   
Distance 
(Å) Angle   
Distance 
(Å) Angle 
Lys 101 C=O 2.06 98.55° SO2 2.10 115° SO2 4.27 -- SO2 3.00 -- 
Tyr 181 CP 2.54   CP 4.20   CB 4.61   t-Bu 5.09   
Tyr 183   7.23     7.85     7.54     7.88   
Tyr 188   5.96     5.60     4.6     4.30   
Trp 229   4.49     4.54     4.01     4.55   







   
Table 3. Distance of NNIBP residues to ligands and angles of 
hydrogen bonds if present with mutant RT Y181C (Y181C). 
(CP = cyclopropyl; Ar = aromatic ring; CB = cyclobutyl; t-Bu = 
tert-butyl.79 
    













bond   
Distance 
(Å) Angle   
Distance 
(Å) Angle   
Distance 
(Å) Angle 
Lys 101 C=O 2.31 97.76° SO2 2.19 119.06° SO2 2.31 124° SO2 2.13 127° 
Cys 181 CP --   CP --   CB --   t-Bu --   
Tyr 183   7.26     7.86     7.7     7.19   
Tyr 188   3.99     4.32     4.41     4.19   
Trp 229   4.04     5.24     4.87     4.75   
Tyr 318 Ar 5.00   Ar 4.86   Ar 4.85   Ar 4.74   
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of 115 compared to efavirenz at 98.55. An example of a sultam binding in the NNIBP 
can be seen in Figure 17. 
 
 








Figure 18. Efavirenz (green) with 3-methylphenyl sultam (red) in NNIBP of 
wt RT. 
 
Figure 18 shows the sultam (S)-3-(3-methylphenyl)-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxide in the NNIBP of wt RT with efavirenz. Compared to 
efavirenz, it is located in a different configuration in the binding pocket while still 
conforming to the traditional butterfly wing shape. The 3-methylphenyl sultam is the 
most biologically active sultam synthesized to date with an EC50 of 0.037 M, while 
efavirenz has activity in the nanomolar range. However, if the 3-methylphenyl sultam is 
compared to the cyclopropylethynyl derivative sultam in Figure 17 and efavirenz, the 
cyclopropylethynyl looks to interact in a similar fashion as that of efavirenz but with its 
Lys 101 
Tyr 188 Trp 229 
Tyr 181 
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own unique binding interactions. The results shown in Figure 17 gave a positive 
reinforcement of the pursuit to synthesize the alkylethynyl sultams. 
Table 3 shows the data of efavirenz and the three sultams within the NNIBP of 
the mutant strain of RT Y181C (Tyr 181  Cys 181). The first point to notice with the 
mutant interaction is that all three sultams have strong interactions with Lys 101 either 
being closer or equal to that of efavirenz at 2.31 Å. The presence of cysteine has 
changed the interaction of the sultams greatly, although there is a lack of interaction 
with cysteine itself with the absence of an aromatic ring in the amino acid residue. The 
other interactions occurring throughout the pocket seem to resemble that of efavirenz 
relatively closely. With the mutant strain, each sultam shows a hydrogen-bond 
interaction with angles roughly between 120 and130 compared to efavirenz at 97.76. 
Figure 19 shows the theoretical binding structure of the ethynylcyclopropyl sultam with 
efavirenz in the mutant Y181C RT. The sultam is in red and efavirenz is white. The two 
have very similar positioning within the NNIBP of the mutant RT. Efavirenz is one of the 
few NNRTIs that can still be partially active with the mutant strain, and looking at the 




Figure 19. Efavirenz (white) and cyclopropylethynyl sultam (red) in NNIBP of 
mutant RT Y181C.79 
 
 The bis-alkylated sultams were too large to perform docking studies in wt RT, but 
were able to be docked into the Y181C RT pocket.79 Table 4 shows the distances of the 
sulfonyl and the alkyl groups attached to the alkyne of the bis-alkylated sultams to the 
important residues of the Y181C binding pocket. Interestingly, the modeling program did 
not show a result of the distance between the mono-alkylated sultams and the Cys 181 
residue, but the bis-alkylated compounds are within the distance to be considered a 








shows the shape the bis-alkylated compounds form to within the binding pocket. The 
overall confirmation is very different than that of efavirenz leading to the inability to 
predict the possible binding accurately. 
 
Table 4. Distances between biscyclopropyl and bis-tert-butylethynyl sultams and 
key residues in Y181C rt. CP = cyclopropyl and t-Bu = tert-butyl 
  biscyclopropylethynyl 
bis-tert-butylethynyl 
sultam 
Residue in Y181C   Distance (Å)   Distance (Å) 
Cys 181 SO2 3.96 SO2 2.37 
Tyr 183 CP (A) 5.72 t-Bu (A) 7.32 
Tyr 188   5.77   5.01 
Trp 229   4.33   4.42 






Figure 20. Bis-cyclopropylethynyl sultam (purple) and bis-tert-butylethynyl sultam 
(red) in the Y181C binding pocket with nevirapine (white).79 
 
 Figure 21 shows the compound (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-
2,methyl-1,2-benzisothiazole 1,1-dioxide in the NNIBP of wt RT with efavirenz. 
Compared to the similar structure of 3-methylphenyl sultam in Figure 18, the 
cyclopropylphenyl sultam shows a closer fit to efavirenz. Rings A and B of the sultam 
are closer to overlapping the efavirenz Rings A and B, and the cyclopropyl group of the 
sultam. Although it is not in the same position, it is in the same area as the cyclopropyl 











Figure 21. 3-Cyclopropylphenyl sultam (red) with efavirenz (green) in NNIBP of wt 
RT. 
 
The binding studies give a theoretical insight to the ability for the sultams to 
inhibit RT, and in most cases indicate a probable chance of high activity. 
I. CoMFA Modeling 
1. CoMFA 
Comparative molecular field analysis (CoMFA) is a useful tool in in silico 
quantitative structureactivity relationship (QSAR) studies to aid in predicting possible 
biological behaviors of new compounds using a method derived from the relationships 
Lys 101 
Trp 229 Tyr 181 
Tyr 188 
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of a set of already tested compounds with known properties.81 The idea of CoMFA 
came from three points of observations in QSAR like studies: most relevant numerical 
property values would be shape-dependent, non-covalent interactions produce 
observed biological effects, and molecular mechanic force fields, typically steric and 
electrostatic forces, account for a variety of observed molecular properties.  
CoMFA collects data from field values at lattice intersections of automatically 
calculated parameters of energies of sterics (van der Waals) and electrostatic 
(coulombic) interactions between the compound of interest and a “probe atom” placed 
at various intersections of a regular three-dimensional lattice large enough to surround 
all of the compounds in the series (Figure 22).81 The van der Waals values are 
dependent on the force field applied (Tripos, MM3, MM4. etc.) and the atomic charges 
are dependent on what charges are applied to the series (GasteigerMarsili, 
GasteigerHückel, etc.). The probe atom is diagnosed by default with the properties of 
an sp3 carbon and a charge +1.0. When the probe atom experiences a steric repulsion 
greater than what is called the “cut-off,” the steric interaction is set to the value of that 
“cut-off,” and the electrostatic interaction is set to the average of the other molecules’ 
electrostatic interactions at the same location.81 From here, a partial least-squares 
(PLS) method is employed to extract QSAR data from the data table, and a QSAR 





Figure 22. The CoMFA process.81 
 
 After setting the force field and the charges, CoMFA’s most important input 
variable in positioning of the molecular model within the lattice is highly dependent on 
what is called the “alignment rule,” because of the dependence of the relative interaction 
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energies on relative molecular positions. The molecules in the series are to be aligned 
together through space in a “field-fit” manner in order to set the molecules in positioning 
of the fixed lattice.81 Once the “alignment rule” has been met, the last of the input data is 
the known biological activity value of each compound. This is entered into the program 
in a table as the log of each value of biological activity. From here, CoMFA outputs data 
that includes a cross-validated r2, the “coefficient contour” map displays, and the 
desired prediction values of compounds with unknown data.82 
2. MM4 Force Field 
 The minimalization force field applied to the sultams in this project was the 
molecular mechanics 4 (MM4) force field. The MM4 force field was developed to 
improve upon the calculation of vibrational frequencies, rotational barriers, and various 
relatively small errors found in the MM3 force field.83 Since MM3 was already useful and 
decent with few substantial errors, it was used as the template for the design of the 
MM4 force field. An accurate force field of compounds is dependent on three 
moderately coupled parts: structure, vibrational spectra, and the heats of formation. The 
MM3 force field was developed in 1989 to improve upon the MM2 force field developed 
in 1977 that only gave a good interpretation of organic compounds. From here, the MM3 
force field allowed the calculation of vibrational spectra with fair accuracy and thus 
allowed the calculation of certain thermodynamic properties. The MM3 force field has 
been labeled as a class 2 force field with its use of harmonic terms, explicit diagonal 
effects, cubic and higher terms, and explicit off-diagonal elements to the force constant 
matrix (mechanical terms). A class 3 force field would take into account these 
mechanical terms while also including chemical effects such as electronegativity and 
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hyperconjugation. From here, the MM4 force field was developed to improve the MM3’s 
insufficient accuracy of vibrational spectra, rotational barriers for congested molecules 
low calculations, the lack of vibrational energy being taken into account for heats of 
formation calculations, and small improvements on structures of simple compounds on 
the whole.84 
Following the improvements on the MM3 model, a set of cross terms was added 
to the MM4 force field to improve the force field. The cross terms involved were bend-
torsion-bend, torsion-improper torsion-improper torsion, and stretch-stretch terms. 
These new terms work together to improve upon the method without taking away the 
effect of each other. The new terms work to improve the coupled in-plane bending, the 
out-of-plane bending, and stretching vibrational frequencies, in that order.85 
      3. GasteigerMarsili Charges 
Atomic charges can be calculated through several methods in computer 
modeling programs by characterizing the atoms by their orbital electronegativies. The 
GasteigerMarslili method goes on to include the effect of the connectivities of the 
atoms in a molecule to further advance the calculation of charges based on 
electronegativity. Using the connectivities, not only are the orbitals of a particular atom 
involved in the calculation, but the effect of neighboring orbitals as well, therefore 
involving the inductive effect.86   
J.  Summary 
With the identification of HIV as the causative agent of AIDS,3 which is one of the 
landmark discoveries in the history of medicine, the challenge was put into the hands of 
the medicinal chemist to develop therapies to either eradicate87 or at least limit the 
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development of the virus. By making use of a precise knowledge of the lifecycle of the 
HIV virus, a number of points for pharmaceutical intervention were identified, among 
them the reverse transcriptase process.23 To this end, medicinal chemists have worked, 
using molecular modeling and QSAR studies to design non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) that have shown substantial activity against HIV. 
These, and a handful of other drugs acting on other points of attack, either alone or in 
combination, are today the only successful anti-HIV therapies, given that fact that a 
vaccine against the virus remains elusive.88 
That which remains to do in the Baker group is to extend the molecular modeling 
and CoMFA studies on the binding of a class of non-nucleoside RT inhibitors called 
“sultams” to improve both potency and activity toward resistant HIV strains.72, 79 The 
Baker group has developed methods to selectively synthesize specific enantiomers for 
a large number of sultams and has developed considerable structurederivatives of 3-
substituted-1,2-benzisiothiazole 1,1-dioxides. Taking the lead of efavirenz, a successful 




Chapter II. Statement of the Problem 
 AIDS is still a large problem throughout the world today, with HIV being the 
cause of the epidemic. Many forms of treatment have come along to help reduce the 
mortality rate of the disease with inhibition of reverse transcriptase being a popular 
method of inhibition. It is our hope that our proposed compounds will be effective 
against wt RT and mutant strains of RT. After FlexiDock modeling work performed by 
Dr. Kafri, the use of another modeling method called CoMFA is to be used to further aid 
in predicting possible activities of the proposed compounds. Using calculations to 
analyze compounds with known biological activities, an r2 value, a coefficient of 
determination, is to be determined to help predict theoretical EC50 values for the sultams 
to be designed and synthesized in this project. 
 Previous research by Dr. Kafri looked into synthesizing the three bis-alkynyl 
compounds shown in Figure 16 along with the three mono-substituted compounds. In 
her research, she declares success in the synthesis of 3,3-bis(cyclopropylethynyl)-2,3-
dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, 3,3-bis(cyclobutylethynyl)-2,3-
dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, 3,3-bis(tert-butylethynyl)-2,3-dihydro-
2-methyl-1,2-benzisothiazole 1,1-dioxide, and (S)-3-(tert-butylethynyl)-2,3-dihydro-2-
methyl-1,2-benzisothiazole 1,1-dioxide, none of which required reduction following the 






 In addition were also synthesized compounds of complete reduction (S)-3-
(cyclobutylethyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide and (S)-3-
(cyclopropylethyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide. Evidence 
suggests that in the time since Dr. Kafri has left the department, the bis compounds 
have degraded, and further studies of her data suggests that the mono tert-butylethynyl 
sultam has not been synthesized. This project looks to reproduce her compounds while 
also adding to the database the compounds 3-(tert-butylethynyl)-2,3-dihydro-2-methyl-
1,2-benzisothiazole 1,1-dioxide, 3-(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxide, 3-(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxide, and (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxide, all of which require selective 1,2-reduction of the 
intermediate imine. 
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In previous research on the sultams, methods for synthesizing the alkylated 
sultam in the first step resulted in low yields and without selectivity of a mono or bis 
product. This project will work towards the improvement of the methodology of the 
addition of a lithiated or Grignard reagent to saccharin or pseudo-saccharin chloride 
reaction step of the synthesis to achieve methods with selectivity of one product over 
the other in the case of mono- vs. bis-alkynyl derivatives. The purpose of the research 
into the novel methodology was to improve the yields of the preferred product over the 
undesired side product.  
A third issue discussed in this project involved how previous research showed 
that the S-enantiomer of the sultam class of NNRTIs as the more active enantiomers, 
and the previously discussed Rh catalyst for asymmetric reduction was used to attain 
the desired product. However, once the chiral Rh catalyst was applied to the alkynyl 
sultams, previous research shows that a 1,4-reduction of the ,-conjugated system 
resulted. From this problem, research was performed towards the goal of performing the 
1,2-reduction or possibly isolation of the S-enantiomer. Various methods included, other 
asymmetric reducing reagents, employing the Luche reduction (a racemic reduction 
favoring 1,2- over 1,4-reduction), isolation of the desired S-isomer via chiral resolution 
methods, or protection of the alkynes as cobalt derivatives.  
The final problem to solve was the development of a procedure for the synthesis 
of (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, a 
compound of compelling interests from its FlexiDock model and CoMFA predictions. 
Methods involved looking into performing traditional SimmonsSmith reactions first, 
which later would be altered as to form the cyclopropane ring in the last step with an 
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iodomethylzincphenoxide reagent. From here, issues arose with the separation of the 
(S)-3-(3-vinylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide and the final 
compound 3-cyclopropylphenyl sultam.  
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Chapter III. Results and Discussion 
A. CoMFA Modeling 
     1. Preparing Sultams with Known Activities 
 Each sultam with known activity was drawn in the Sketch Molecule menu of 
SYBYL 8.0. The sultams sketched resembled the structure in Figure 23 where R1 and 
R2 are shown in Table 5. Hydrogen atoms were added, and the MM4 force field 
minimalization was applied followed by the GasteigerMarsili charges. The structures 
were then superimposed onto each other to form a database with the common sub-
structure of (S)-3-phenyl-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, Figure 
23, as the aligning model.  
 
 
Figure 23. Common substructure of sultams with known activities modeled into 








Table 5. Sultams with known activities, their EC50 and the pEC50 for CoMFA 













R1 R2             
phenyl H 0.471 6.327 6.148 0.711 0.179 -0.240 































7.432 6.821 0.151 0.611 -0.114 
m-Fphenyl H 0.179 6.747 6.797 0.160 -0.050 0.019 
m-Clphenyl H 0.086 7.066 7.060 0.087 0.006 -0.001 
m-Brphenyl H 0.074 7.131 7.170 0.068 -0.039 0.006 

































2. Data Input 
A spreadsheet was designed resembling Table 5 with each sultam designed 
being represented by a number in a row and its respective EC50 and calculated pEC50. 
The CoMFA interaction energies were calculated for each compound, and a partial least 
squares analysis was performed to produce the correlation value, R2. Using a non-
validation calculation with three components, an R2 value of 0.890 was determined. The 
manual for use of CoMFA states that an R2 value above 0.65 and below 0.95 to be 
substantial for predictability, with any value above 0.95 as being too ideal to be usable 
data. 
To test the viability of the R2 value from the known sultam compounds used for 
the CoMFA analysis, a cross validation was performed on the same biologically active 
compounds shown in Table 5. The cross-validation results produced predicted activities 
within a 0.0012.1 micromolar range of the known values. The m-halogenated phenyl 
sultams resulted in excellent predictability of the CoMFA analysis with differences in the 
nanomolar range. A few cases resulted in larger differences in the micromolar range, 
such as the o-methylphenyl sultam, which CoMFA predicted a higher activity for this 
compound. The validation results predicted some values to have greater activity in 
some cases and lower activity in others; however, the values were without further 





      3. Preparation of Sultams with Unknown Activities 
 The sultams to be analyzed for a predicted activity were prepared in a similar 
fashion as those with known activities in Section 4 with the MM4 force field, 
GasteigerMarsili charges, and the superimposing with a common substructure of 2,3-
dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide (Figure 24). They shared the same 




Figure 24. Common sub-structure of novel sultams. 
 
      4. Data Output 
 The data output from the CoMFA analysis produced predicted pEC50 values for 
the novel sultams. These values were converted to the EC50 value giving predicted 
activities of the sultams. The predicted most active sultam is the (S)-3-
cyclopropylethynyl-2,3-dihydro-2-methyl-1,2-benzisothiazole with an EC50 of 0.148 M. 
The bis-alkylethynyl compounds were predicted with EC50 values around 0.33 to 0.38 
M. These predictions are only a general idea of the activity of the novel sultams. The 
CoMFA analysis was comparing mainly sultams with an aryl substituent as compared to 






Table 6. Novel sultams with calculated and predicted EC50 and pEC50 values. 
Sultam EC50(M) pEC50 
R1 R2   
cyclopropylethynyl H 0.148 6.831 
cyclopropylphenyl H 0.167 6.776 
cyclopropylethynyl cyclopropylethynyl 0.333 6.477 
tert-butylethynyl H 0.160 6.795 
tert-butylethynyl tert-butylethynyl 0.344 6.464 







The original synthetic method to yield the ethynyl sultams resembles that as 
designed by Baker and co-workers to synthesize (S)-3-aryl-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxide, which was expanded from that of Abramovitch et al where 
two equivalents of an aryl magnesium chloride or bromide Grignard reagent were 
coupled to one equivalent of saccharin to produce the respected 3-(aryl)-1,2-
benzisothiazole 1,1-dioxide (Scheme 5).69, 70, 74 Using this method, a synthesis was 
designed using 2 equivalents of alkynyllithium reagents with saccharin to yield the 
desired 3-(alkylethynyl)-1,2-benzisothiazole 1,1-dioxides (7-1). From here, the 
carbonnitrogen double bond would be asymmetrically reduced by the (R,R)-
[TsDPEN]RhCp* catalyst developed by Baker and co-workers to yield the (S)-3-
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alkylethynyl)-1,2-benzisothiazole 1,1-dioxide product (7-2). The nitrogen atom would be 
deprotonated by cesium carbonate, and the resulting negative charge on the nitrogen 
atom would act as a nucleophile towards the methyl iodide producing the methylated 
nitrogen atom in the product (S)-3-(alkylethynyl)-2,3-dihydro-2-methyl-1,2-





When the project began, methodologies were to be investigated to synthesize 
the compounds (S)-3-(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-
dioxide, (S)-3-(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, 
and (S)-3-(3-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide, 
as shown respectively, in Figure 25. Furthermore, the project was to also look into 
samples developed by Dr. Riyam Kafri (Figure 26), which upon analysis, signs of 
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possible degradation may have occurred, and the compounds would need to be 







2. 3-(Alkylethynyl)-1,2-benzisothiazole 1,1-dioxide (10-110-3) 
Two issues arose in the above-proposed method to synthesizing the alkylethynyl 
sultams. Firstly, the lithiated alkynyl compounds, when reacted with saccharin, 
produced the mono-alkynyl sultams in low yield, while also resulting in the production of 
bis-alkylated products. The second issue was that the use of the rhodium catalyst for 
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the asymmetric reduction would result in 1,4-reduction instead of the desired 1,2-
reduction. The first problem that will be discussed is the development of a method to 
improve the synthesis of mono-alkylethynyl-1,2-benzisothiazole 1,1-dioxide while 
limiting the production the bis-alkylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide. 
As stated previously, when performing the addition of the lithiated alkynes to 
saccharin, the yield of the mono-substituted sultam (8-1) was substantially low 
compared to the addition of aryl magnesium bromides. The product of the bis-alkylated 
product (8-2) was also detected as determined by DARTHRMS and 1H and 13C NMR 
spectroscopy (Scheme 8). It was determined that from here a new method was to be 
developed that improved the selectivity of the product and the yield of the mono-
substituted product. A goal was to also design another method to produce the bis-




As discussed by Abramovitch et al.,74 another compound named 3-chloro-1,2-
benzisothiazole 1,1-dioxide (saccharin pseudo-chloride) was shown to react with 
lithiated alkanes to produce similar compounds. To produce the saccharin pseudo-
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chloride (9-1), saccharin was dissolved in 1,4-dioxane, and an excess of thionyl 
chloride was added to the solution. A catalytic amount of N,N-dimethylformamide was 
added to perform the reaction under Vilsmeier-like conditions (Scheme 8).89 The 
reaction was stirred at reflux for two days, and brought back to room temperature. The 
reaction mixture was rotary evaporated to remove solvent, and then recrystallized 
using hot toluene producing white crystals of the chloro derivative.  
 
 
The reactivity of the saccharin pseudo-chloride (9-1) was shown to be greater 
than that of saccharin itself, which resulted in the production of the bis-alkylated product 
in higher yield under the right conditions. From here, methodology was designed to 
favor the mono- over the bis-product and another method to favor the bis- over the 
mono-product.  
In an attempt to produce more of the mono-alkylated product relative to the bis-
product, because of the saccharin pseudo-chloride’s (9-1) higher activity, it was decided 
to use 1.5 equivalents of the chloride 9-1 to 1.0 equivalent of the lithiated alkyne. 
Furthermore, the reaction was performed by slowly injecting the lithiated alkyne into a 
solution of the saccharin pseudo-chloride (9-1) over a period of 1 hour at 78 C. Under 
these conditions, the saccharin pseudo-chloride (9-1) always would be at a substantially 
 69 
much higher concentration than the lithiated alkyne at cold temperatures, resulting in 
the nucleophile to favor a mono-addition over the bis-addition (Scheme 9). This method 
on average produced around 60% yield of the desired mono-product when the alkyne 
was commercially available in high purity (10-1 (70%) and 10-3 (59%)). 
 In the case of the cyclobutylethynyl derivative 10-2, the ethynylcyclobutane 
precursor was synthesized from 6-chlorohexyne (11-1) with 2 equivalents of n-BuLi 
under anhydrous conditions starting at 78 C with warming to room temperature 
overnight.90 It was found that the product of that reaction, before work-up, was typically 
cyclobutylethynyl lithium (11-2) and was therefore added directly to a solution of 1.5 
equivalents of saccharin pseudo-chloride (9-1) (Scheme 10). Due to the boiling point of 
ethynylcyclobutane being so close to THF, the purification by distillation of the 
compound from THF proved impossible, thus limiting its purity for the lithiation reagent. 
Because of the immediate addition of the synthesized lithiated ethynylcyclobutane (11-







In steps taken toward producing the bis-alkylated products, a number of factors 
were considered in adjusting the conditions for the synthesis of the mono-alkylated 
products in order to reverse the outcome. After performing the steps to produce the 
lithiumhydrogen exchange on the alkynes, 0.5 equivalents of saccharin pseudo-
chloride (9-1) were slowly added dropwise to the solution of the lithiated alkyne at 78 
C (inverse addition), which was warmed to 10 C over a period of 1 hour (Scheme 12). 
This method allowed the lithiated alkyne to be greater in concentration compared to the 
saccharin pseudo-chloride (9-1) at all times. After the work-up and column 
chromatography, the method produced close to a 70% yield for bis-derivatives 12-1 
(69.5%) and 12-3 (88%), while that for 12-2 was lower (15%) due to the impure lithium 





As shown in Mechanism 1, the mono-imine product is postulated to form by the 
addition of the alkyne at the electrophilic carbon atom attached to the nitrogen atom 
and the chlorine atom, thereby pushing electrons onto the nitrogen atom. From here, 
the electrons re-form the double bond resulting in the chlorinecarbon bond breaking 
and the Cl- leaving. For the mono-substituted product, work-up with satd NH4Cl is used 
to quench any remaining base. The second line in Mechanism 1 shows how the 
second equivalent of the alkyne is added to the same carbon atom center pushing the 
electrons onto the nitrogen atom once more, but from here, the use of a slightly acidic 
work-up protonates the nitrogen atom and ends the reaction. To confirm that this was 
how the formation of the bis-alkylated product was proceeding, a reaction was 
designed where pure 3-cyclopropylethynyl-1,2-benzisothiazole 1,1-dioxide was 
dissolved in dry THF, brought to 78 C, and one equivalent of lithiated 
ethynylcyclopropane was added to the solution. Formation of the bis-product was seen 
showing how the second equivalent of the lithiated alkyne could add once more in the 
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As discussed by Abramovitch et al., the methodology for the synthesis of the bis-
alkylated versus the mono-alkylated product needed improvement.74 Abramovitch et al. 
typically produced 10% of the mono-alkylated product and 24% of the bis-alkylated 
product by their methods.74 The method employed by Kafri produced around 40% yields 
and showed no selectivity in mono- versus bis-product production.79 By the change in 
the order and speed of addition, temperature control, and taking advantage of 
concentration ratios, the yields of the bis- versus the mono-products were adjusted to 
favor one product over the other successfully and in greater yields. At this point, a 
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methodology for performing 1,2-reductions on the mono-alkylethynyl sultams would be 
investigated. 
3. 3-(Alkylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-116-3) 
As previously discussed, a paper by Baker and co-workers addressed the design 
and synthesis of a novel catalyst employing the ligands as used by Noyori et al. with the 
reactivity of rhodium towards the reduction of imines.75, 78 Noyori’s catalyst used  
(1S,2S)-p-TsNCH(C6H5)-CH(C6H5)NH2 and various aromatic groups as ligands on 
ruthenium chloride as an asymmetric catalyst for hydrogenation of ketones with high 
ee.75 Noyori’s catalyst was shown to work on imine double bonds with varying high ee, 
however, with long reaction times.75 It was found by Dr. Jianmin Mao, while in Dr. 
Baker’s lab, that rhodium-based catalysts showed strong affinity for reactions with 
imines.77, 78 The rhodium catalyst performed asymmetric hydrogenation with a 5:2 formic 
acidtriethylamine azeotrope on the 3-aryl-1,2-benzisothiazole 1,1-dioxides (13-1) with 





In Dr. Kafri’s research it was found that when used to reduce two of the 3-
alkylethynyl-1,2-benzisothiazole 1,1-dioxides (10-1 and 10-2), the chiral rhodium 
catalyst (Figure 14) would not only reduce the imine bond in a 1,2-reduction fashion, but 
also the triple bond due to the ,-conjugated system in these compounds, performing a 
complete reduction.79 This would result in the production of 3-alkylethyl-2,3-dihydro-1,2-
benzisothiazole 1,1-dioxides (14-1) (Scheme 14). However, Dr. Kafri stated that when 
the rhodium catalyst was used to reduce 3-(tert-butylethynyl)-1,2-benzisothiazole 1,1-
dioxide (10-3), the 1,2-reduction was performed to produce 15-1, as shown in Scheme 
15.79 As with the bis-alkylated sultams, the material for 15-1 had degraded; therefore, 
the synthesis of 15-1 would also be a part of the work performed. Further studies by 
performing the reaction and investigating as per Dr. Kafri’s methods did not yield 15-1. 
Upon a more detailed investigation of the 1H and 13C NMR of (S)-3-(tert-butylethynyl)-
2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (15-1) doubts in the synthesis of the desired 
product arose. This led to the inclusion of compound 10-3, the tert-butyl imine, in the 







The first attempt to perform the 1,2-reduction was to use a mild reducing agent 
such as NaCNBH3 in methanol with the idea that it would not be reactive enough to 
perform the 1,4-reduction. However, this, too, would perform the 1,4-reduction while 
also performing the racemic reduction resulting in the 50:50 mixture of 3-alkyl-2,3-
dihydro-1,2-benzisothiazole 1,1-dioxide. Seeing as this was not a desired product, the 
method was abandoned.  
After further investigation, the Luche reduction, which has been shown to perform 
a racemic 1,2-reduction of ,-conjugated ketone systems, was attempted.91 Further 
hopes for the application of the Luche reduction was found in a reaction of a patent for 
pyrazolyl-amino substituted pyrazines where the conditions for the Luche reduction 
were applied to an imine bond adjacent to an aromatic ring.92 From here, the Luche 
reduction was applied to compound 10-1 first to test usefulness of the reaction. Results 
found that the Luche reduction can also be applied to an imine functionality with ,-
conjugation to give an alkyne in a heterocyclic system with high yield of approximately 
75% (Scheme 16).  This was unique at the time, because the only application of the 
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Luche reduction to imines involved the imine in conjugation with aromatic rings instead 
of alkynes or alkenes. 
Due to the lower reactivity of the nitrogen atom in an imine bond, when compared 
to the oxygen in a carbonyl bond, the method involved reacting the 3-alkylethynyl-1,2-
benzisothiazole 1,1-dioxides (10-110-3) with 1.5 equivalents of CeCl3 for 1 hour at 
room temperature before addition of 1.5 equivalents of NaBH4 in 100% ethanol at 0 C. 
The reaction was stirred at 0 C for 30 minutes before warming to room temperature 
and stirring for one hour. It was later investigated to attempt the Luche reduction with 
CeCl37H2O, a cheaper alternative to the anhydrous CeCl3, with positive results. Since 
the application of the Luche reduction in this project, a paper was published in 2012 
discussing the procedure of using Luche reduction conditions on hexaazamacrocycles-
like compounds to reduce conjugated imines, but again, the conjugation was with 
aromatic rings instead of an alkyne or alkene that risked the chance be reduced in a 1,4 
fashion.93 This gives evidence that the application of the Luche reduction to ,-





Upon the synthesis of racemic 16-3, a comparison of its NMR spectra to those of 
Dr. Kafri for the purported 15-1, it was concluded that the compound had not been 
synthesized. In Dr. Kafri’s 13C spectrum of 15-1, the carbon peak of the C=N is still 
present; furthermore, in her 1H spectrum, there is a singlet proton peak around 6.2 ppm, 
which, the proton spectrum for 16-3 shows two proton peaks at 4.81 ppm for the 
hydrogen atom on the nitrogen atom in 16-3, and 5.41 ppm for the hydrogen atom on 
the carbon atom adjacent to the nitrogen.79 
As discussed previously, this method produced a high yield of the racemic 
products (16-116-3), and a procedure was sorely needed for synthetically producing 
the pure (S)-enantiomer of the desired 3-(alkylethynyl)-2,3-dihydro-1,2-benzisothiazole 
1,1-dioxides.  
From here, methods were explored to attempt coupling of the now 3-alkylethynyl-
2,3-dihydro-1,2-benzisothiazole 1,1-dioxides (16-116-3) with an amino acid with 
defined stereochemistry as an attempt to induce a chiral resolution that can be used to 
manipulate the presence of diastereomers in column separations. The amino acid L-
phenylalanine was chosen for coupling with the nitrogen atom of the heterocycle in 
attempts to form a peptide bond. 
The first attempt in the project for coupling the nitrogen atom of the sulfonamide 
functionality was to look at the use of amino acid coupling reagents. According to 
Backes and Ellman, the coupling reagent PyBOP, has shown substantially good results 
when coupling Ellman’s modification of Kenner’s sulfonamide linker (Figure 27) resin 
with a Boc-protected L-phenylalanine with a yield of 90% in DCM at 20 C with i-
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Pr2EtN as the base.
94 When compared to other peptide coupling agents, Ellman’s 
modification has also been used by Marcaurelle and Bertozzi to synthesize deptericin 
and by Mende and Seitz to synthesize peptide -thioesters with protection by Fmoc 
instead of Boc.95, 96 The idea was investigated to look into the idea of a heterocyclic 
sulfonamide reacting under similar conditions as the primary alkanylsulfonamide in the 
resin. The same conditions were maintained for the first attempt, and 3-
cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-1) was reacted with 
L-Boc-Phe-OH with PyBOP as the coupling reagent (Scheme 17).  Using the DART-
MS, evidence of the mass of the product appeared, but subsequent column 
chromatography produced very little of the coupled product. Alterations of time and 
temperature also proved to not yield a substantial amount of product, leading to a 








A different approach was attempted when several papers presented the idea of 
reacting the 3-alkylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-116-3) with 
a base to deprotonate the nitrogen, which would then react with an acyl chloride to form 
the peptide bond.97, 98 Oppolzer et al. performed various methods of acylating either (S)-
3-methyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide or camphorsultam with either acyl 
chlorides or with trimethylaluminum and an ester.97 One attempt used the (S)-methyl 
sultam 19-1 with propionyl chloride (Scheme 19). Seeing as Oppolzer used a sultam 
very similar to 16-1 instead of a primary solid-phase sulfonamide like those in Figure 25, 
the same method was attempted with racemic 3-cyclopropylethynyl-2,3-dihydro-1,2-
benzisothiazole 1,1-dioxide (16-1) with N-Cbz-L-phenylalanine acyl chloride. 
Triethylamine was used to deprotonate the nitrogen atom of the heterocycle, which 
would then be expected to attack the carbonyl carbon of the acyl chloride producing the 





The coupling with the use of the acyl chloride of the amino acid and the racemic 
3-cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-1) gave no positive 
results. When compared with the method of Oppolzer et al., the sulfonamide 19-1 
already had defined stereochemistry with only a methyl group at the 3-position as 
compared to the racemic cyclopropylethynyl substituent.97 Furthermore, Oppolzer et al. 
performed the coupling with propionyl chloride to form 19-2 as opposed to the bulkier N-
Cbz-L-phenylalanine acyl chloride (Scheme 19). It is believed that the sterics of the 
racemic ethynyl sultam compared to the S methyl sultam and the sterics of the Cbz-





From here, a look into other possibilities for performing the amino acid coupling 
with the racemic 3-cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-1) 
was investigated to discover that Oppolzer and co-workers and various other groups 
also performed the acylation with the use of trimethylaluminum to couple sulfonamides 
with the carbonyl of an ester.99-103 To achieve the ester of the N-Cbz-L-phenylalanine, 
the Cbz protected amino acid was reacted with thionyl chloride in methanol. From here, 
the sultam was reacted with trimethylaluminum in anhydrous toluene under argon 
followed by the N-Cbz-L-phenylalanine methyl ester to attempt to synthesize 20-1 





As with the use of the acyl chloride, this reaction was not successful, with 
theories believing it was also because of steric hindrance. It was decided to attempt the 
same procedure with varying protecting groups on the nitrogen atom of the amino acid. 
Of the protecting groups attempted were a Boc-group, dibenzyl-, and methyl- and 
benzyl-protected amines. The method failed to produce positive results in any of the 
varying compounds, except the Boc-protected group did react, however, not at the 
methyl ester site as shown by NMR analysis. The first indication of the product not 
occurring at the methyl ester was the presence of a single methyl peak integrating to 3H 
as compared to the integration of the single proton in the sultam ring. Furthermore, 
using 2-D NMR analysis, it was determined that a peptide bond was formed at the 
carbonyl carbon atom of the Boc protecting group because the hydrogen on C3 in the 
sultam ring correlated to a carbonyl carbon. The carbonyl carbon did not show a 
correlation to the CH2 group in the phenylalanine as it should if the carbonyl were 
bonded to the nitrogen atom was from the methyl ester carbonyl. Therefore, the reaction 
occurred at the Boc carbonyl and the tert-butoxide group acted as a leaving group, 





In the end, it seemed the use of L-phenylalanine, protected or not, would not 
couple to the racemic 3-cyclopropylethynyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide 
(16-1). The issue of sterics arises with the reasoning of the coupling not occurring. In 
the works cited,97, 98, 101-103 the authors either used a sultam with a defined stereocenter 
with only a methyl substituent versus our racemic cyclopropylethynyl group, or an 
alkanesulfonamide. Most of the authors also used a group for the acylation that was not 
itself defined with stereochemistry but rather small and/or flat near the acylating 
carbonyl. 
From here, different methods were considered for reducing the imine bond 
without affecting the triple bond. The use of a compound nicknamed BINAL-H (R isomer 
in Figure 26) by Noyori, comprised of reacting LAH with either the R or S isomer of 2,2’-
dihydroxy-1,1’-binapthol and a simple alcohol (MeOH or EtOH) was considered.104 
Noyori et al. found that BINAL-H with ethanol could reduce various ketones 
asymmetrically with high ee under cold conditions. When applied to an ,-conjugated 
system, BINAL-H showed a preference for asymmetric reduction while also performing 
the 1,2-reduction over the 1,4-reduction.  BINAL-H has been applied to the asymmetric 
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reduction of phosphinyl imines, which gave hope to it working on the cyclic sulfonyl 
imine.105 It was with this knowledge that the method and reagent would be applied to 
the reduction of 3-cyclopropylethynyl-1,2-benzisothiazole 1,1-dioxide (10-1) (Scheme 
22).  After several attempts, the analysis of the results of the reaction in Scheme 22 
showed that no reaction took place. Conditions were altered to longer reaction times 







The next attempt was to use Co2(CO)8 as a protecting group on the alkyne. Upon 
reacting the 3-cyclopropylethynyl-1,2-benzisothiazole 1,1-dioxide (10-1) with Co2(CO)8, 
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the complex 23-1 with the alkyne was formed according to what appeared as 
broadening of peaks in the NMR due to the presence of the cobalt that matched with the 
proton shifts of the cyclopropylethynyl sultam proton spectrum (Scheme 23).106-108 After 
seeing the presence of the cobalt complex, the asymmetric reduction was attempted 
with the chiral rhodium catalyst designed by Baker and co-workers.78 The reaction 
appeared to occur only by evidence in the spectrum from the DARTMS with a trace of a 
+H m/z of 234, the mass of 16-1 without the presence of the cobalt protecting group. 
Column chromatography failed to produce a tangible amount of pure material. Looking 
at the 3-D shape of the cobalt-complexed sultam (Figure 29), the three carbonyl groups 
on the cobalt tend to point in various directions of the structure leading one to believe 
that they could cause steric interference with the ligands of the rhodium catalyst, thus 









Figure 29. Compound 23-1, the cyclopropylethynyl sultam with the alkyne 
protected with the cobalt carbonyl complex. 
 
After a search through the literature, one paper by Corey and co-workers showed 
the use of a chiral oxazaborolidine with catelcholborane to perform the 1,2-reduction on 
,-ynones asymmetrically with high ee without affecting the triple bond.109, 110 With the 
Luche reduction occurring primarily on ketones, but also being a feasible method for the 
reduction of ,-conjugated imines (Scheme 16), the use of the oxazaborolidine was 
applied to the reduction of the sultam as well. The catalytic oxazaborolidine 24-1 was 
prepared from (S)-,-diphenyl-2-pyrrolidinemethanol and Me3SiCH2B(OH)2. It was 
reacted with the cyclopropylethynyl sultam 10-1 with catelcholborane at 78 C to room 
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temperature over night (Scheme 24). After work-up and column chromatography, NMR 
spectra and DARTMS indicated a 20% yield for the reduced sultam 24-2, and the triple 
bond was not affected, therefore the 1,2-reduction occured. To test for the asymmetric 
reduction the sample was analyzed with a polarimeter to assess the optical activity. 
Polarimetery at multiple wavelengths showed no rotation, leading one to believe there 
was no optical activity; therefore, the reduction occurred, but not asymmetrically. This 
method was no longer pursued as it performed the same racemic reduction as the 




After the above-mentioned attempts had been ruled out as viable methods for a 
selective 1,2-asymmetric reduction, it was decided to rely on the Luche reduction and to 
evaluate the biological activity of the racemic mixtures. Once the biological activity data 
are collected, if the data seems worth pursuing the pure enantiomers, the use of chiral 
columns for HPLC will be investigated for the purification of the enantiomers. As of this 
time, some limited chiral separations have been attempted using the available ChiralCel 
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D column, which was used in the Baker group to separate the racemic mixtures of the 
3-methylphenyl and similar derivatives by the original method, and a ChiralCel AD 
analytical chiral column. No meaningful separations were achieved. More extensive 
work using a set of chiral columns, followed by selective (and expensive) 
semipreparative columns would be necessary. 
Mechanistically, the Luche reduction proceeds by the lone pair on the nitrogen 
atom forming a complex with the CeCl3, resulting in the carbon in the imine bond 
becoming more electrophilic. Furthermore, the presence of the ethanol causes the 
sodium borohydride to become a harder nucleophile by replacing the hydrides with 
ethoxide groups. From here, the hydride adds the hydrogen to the carbon of the imine 
bond pushing electrons to the nitrogen atom, where after work-up the product is formed 






4. 3-Alkylethynyl-2,3-dihydro-3,methyl-1,2-benzisothiazole 1,1-dioxide and 3,3-
bis(alkylethynyl)-2,3-dihydro-3-methyl-1,2-benzisothiazole 1,1-dioxide (25-
125-6)  
The final step for the product of the mono-alkylethynyl sultams (25-125-3), 
including the bisalkylated-products (25-425-6), involved methylating the nitrogen atom. 
The process involved the use of the inorganic base Cs2CO3 in an organic solvent in 
which it was soluble, acetonitrile or N,N-dimethylformamide. The base deprotonates the 
nitrogen atom, where after the addition of iodomethane, the electrons attack the carbon 








Original methods to synthesize compound 26-4 involved initially performing the 
SimmonsSmith cyclopropanation on 3-bromostyrene. This was performed via a 
traditional SimmonsSmith method with a zinccopper couple and diiodomethane. The 
cyclopropanation occurred as evidenced by the presence of the mass of the product in 
a GC/MS spectrum; however, upon attempts to form the organometallic form of the 
compound (lithiated or Grignard reagent), the organometallic was not formed. Past 
results showed use of n-BuLi possibly opened the cyclopropane ring or formed a 
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dimeric linked version of the compound, and evidence suggests that the Grignard 
reagent, 3-cyclopropylphenylmagnesium bromide was never formed. From here, it was 
decided to attempt the cyclopropanation reaction in the last step of the synthesis to 26-
4. 
The method for preparing 3-(3-vinylphenyl)-1,2 benzisothiazole 1,1-dioxide (26-1) 
follows a method similar to that designed by Baker and co-workers, which resembles 
that of Abramovitch et al.74 While a Grignard reagent of 1.0 equivalent of 3-
bromostyrene is synthesized with magnesium turnings, a solution of 0.9 equivalents of 
saccharin in THF is reacted with 0.9 equivalent of phenylmagnesium bromide to 
deprotonate the nitrogen atom of saccharin. Once one equivalent of the 3-vinylphenyl 
magnesium bromide was prepared, it was added to the deprotonated solution of 
saccharin to act as a nucleophile at the carbonyl carbon, and the product was formed 
after work-up followed by column chromatography. Compound 26-1 was obtained in a 
62.2% percent yield (Scheme 26, 26-1).35  
The asymmetric reduction was carried out with the chiral rhodium catalyst 
developed by Baker and Mao as it had produced high yields  and high ee values in the 
past on various other derivatives of the 3-phenylsultams.78 The compound 26-1 was 
dissolved in dry DCM, and the catalyst was added with a ratio of 200:1 S:C. An 
azeotrope of 5:2 formic acid to triethylamine was added to act as the hydride source, 
and after a short reaction time of 30 min to 1 h, the reaction was complete and worked-
up the compound (S)-3-(3-vinylphenyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (26-
2) was yielded after column chromatography in 93% yield (Scheme 26). 
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The nitrogen atom was methylated as discussed in previous methods with 
Cs2CO3 and iodomethane in acetonitrile to give 26-3 at 39% yield (Scheme 26). 
The vinyl group on 26-3 was reacted under SimmonsSmith conditions to form a 
cyclopropyl ring at the 3-position of the phenyl ring. The first attempt was tried with the 
standard SimmonsSmith method using a copperzinc couple in THF with CH2I2 as it 
was conducted on 3-bromostyrene. This method yielded little product, leading to a 
search for other methods. Charette et al. have reported the use of various phenoxides 
with diethyl zinc and diiodomethane to synthesize an iodomethylzinc phenoxide as a 
cyclopropanating reagent.111 The paper discussed several phenols with halides in the 
ortho and para positions as being effective reagents, along with pentafluorophenol 
having similar reactivity to perform the cyclopropanation on styrene.111 Following this 
lead, pentafluorophenol was reacted with diethylzinc, followed by CH2I2, to produce the 
cyclopropanating reagent that was then added to a solution of compound 26-3 in dry 
DCM and allowed to react for two days producing 26-4 in 53% yield. (Scheme 26).  
An issue arose with the purification of 26-4 in that the rf values of 26-4 and 26-3 
are identical under various solvent system methods. By analysis of NMR integration and 
HPLC, the purity of 26-4 appears to be around 90%, and this is adequate enough for 
biological analysis as the biological activity of 26-3 is already known. Compound 26-4 is 






Chapter IV. Experimental Procedures 
 
General 
All reactions were monitored by thin-layer chromatography (TLC). Adsorption 
chromatography was carried out using Sorbent Technologies silica gel products: (a) 
TLC on 0.2 mm aluminum-backed plates, (b) column chromatography using 60200 m 
mesh silica gel. Visualization of the TLC plates was by 254 nm UV light and by dipheat 
development using a p-anisaldehydesulfuric acid reagent.112 All reactions were carried 
out under a nitrogen atmosphere.  
 For every procedure involving dry solvents (THF, DCM, DMF, CH3CN), solvents 
were dried using alumina columns in a PureSolv system, with THF also being distilled 
from sodiumbenzophenone ketyl, and DMF was distilled from calcium carbonate and 
stored in a nitrogen-purged flask with 4 Å molecular sieves. 
 n-butyllithium was purchased from SigmaAldrich as 2.5 M in hexanes, but was 
titrated with a solution of diphenylacetic acid in dry THF to determine the molarities 
shown in the procedures.113 
 All NMR spectroscopy was performed on Varian 500-MHz and 125-MHz NMR 
instrument in CDCl3. Chemical shifts (-values) are reported downfield from 
tetramethylsilane (TMS). Mass spectrometry was performed with a JEOL AccuTOF 
Direct Analysis in Real Time (DART) Mass Spectrometer. 
All glassware and stir bars were dried in an oven overnight at 150 C, and cooled 
in a desiccator before use in reactions. 
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Synthesis of 3-chloro-1,2-benzisothiazole 1,1-dioxide (9-1) 
In a large 1-L round-bottom flask was added 55.2325 g (0.301520 mol) of saccharin 
dissolved 250 mL of 1,4-dioxane. Approximately 90.0 mL (1.25 equiv) of SOCl2 was 
added with 4.0 mL of DMF as a catalyst. The reaction was stirred at reflux for 3 days. It 
was concentrated under vacuum and recrystallized in hot toluene. 1H NMR:  7.807.95 
(4H, m, ArH); 13C NMR:  122.44, 125.10, 129.86, 134.46, 134.97, 140.51 (Ar), 166.11 
(NCCl); DARTHRMS: Calcd for C7H4ClNO2S m/z 200.96513; found [M + H]
+ m/z 
201.97317 (calcd m/z 201.97295).89, 114 
Synthesis of 3-(cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide (10-1) 
 In a dry flask was dissolved 0.5656 mg (8.557 mmol) of ethynylcyclopropane (Organic 
Technologies) in 10 mL of dry THF.  The solution was stirred and cooled to –78 °C 
under a nitrogen atmosphere.  One equiv of 2.3 M n-BuLi solution in hexanes (3.720 
mL) was added via syringe.  The reaction was left to stir for 4 h at –78°C.  A second 
solution of dry THF and 2.5900 g (12.845 mmol, 1.5011 equiv) of 3-chloro-1,2-
benzisothiazole 1,1-dioxide (9-1) was cooled to a temperature of –78 °C under a 
nitrogen atmosphere. It was at this time that the lithiated alkyne solution was added 
dropwise via syringe to the benzisothiazole solution over a period of 1 h at 78 C.  
After the addition was complete, the reaction was left to stir at –78 °C for 1 h, at which 
time it was quenched with satd aq NH4Cl at –78 °C.  The mixture was left to warm to 
room temperature. The product was extracted with Et2O in a separatory funnel, and the 
organic layer was dried with anhyd MgSO4, vacuum filtered, and rotary evaporated.  
The desired product was purified on two separate silica gel columns.  The first elution 
used a 3:1 mixture of Et2O to hexane.  This method separated the mono- and bis-
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formations of the product effectively; however, some compounds coeluted with the 
mono-substituted product in this method.  The second column was eluted with a 3:1 
mixture of DCM to hexane to purify the desired product at 1.3868 g (70.111% yield). 1H 
NMR:  1.091.25 (4H, m, CHCH2), 1.641.73 (1H, m, CHCH2), 7.727.78 (3H, m, 
ArH), 7.837.94 (1H, m, ArH); 13C NMR:  0.80 (CHCH2), 11.01 (CHCH2), 68.51 (CC), 
116.09 (CC), 122.06, 124.94, 131.60, 133.76, 133.96, 138.62 (Ar), 156.62 (C=N); 
DARTHRMS: Calcd for C12H9NO2S m/z 231.27036; found [M + H]
+ m/z 232.04424 
(calcd m/z 232.04322). 
Synthesis of 3-(cyclobutylethynyl)-1,2-benzisothiazole 1,1-dioxide. (10-2) 
In a dry flask was dissolved 665.1 mg (5.705 mmol) of 6-chloro-1-hexyne (11-1) 
(SigmaAldrich) in 10 mL of dry THF. The solution was stirred and cooled to –78 °C 
under a nitrogen atmosphere.  Two equiv of 2.3 M n-BuLi solution in hexanes (5.209 
mL) were added dropwise via syringe over 20 min. After addition was complete, the 
reaction stirred at –78 °C for an additional 20 min, whereupon it was brought to room 
temperature and stirred under nitrogen overnight. The next day, a second solution of dry 
THF and 1.7844 g (1.5512 equiv, 8.8499 mmol) of 3-chloro-1,2-benzisothiazole 1,1-
dioxide (9-1) was cooled to a temperature of  –78 °C under a nitrogen atmosphere, and 
the lithiated ethynylcyclobutane (11-2) solution was added dropwise over 1 h. After 
standing for 1 h at –78 °C under a nitrogen atmosphere, the solution was quenched with 
satd aq NH4Cl at –78 °C. The biphasic mixture was extracted with Et2O, and the organic 
layer was separated and dried with anhyd MgSO4, vacuum filtered, and rotary 
evaporated. The desired product was purified on silica gel chromatography by eluting 
with a 3:1 mixture of Et2O to hexane, followed by a second silica gel chromatography by 
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eluting with 3:1 mixture of DCM to hexane to give the desired product at 245.1 mg 
(17.51% yield). 1H NMR:  2.002.15 (2H, m, CH2CH2CH2), 2.322.42 (2H, m, 
CHCH2CH2), 2.442.52 (2H, m, CHCH2CH2), 3.413.48 (1H, m, CH2CHCH2), 7.737.78 
(3H, m, ArH), 7.867.89 (1H, m, ArH); 13C NMR:  19.45 (CH2CH2CH2), 25.61 
(CH2CHCH2), 29.33 (CHCH2CH2), 73.45 (CC), 114.30 (CC), 122.18, 125.04, 131.34, 
133.86, 133.99, 138.71 (Ar), 156.81 (C=N) DARTHRMS: Calcd for C13H11NO2S m/z 
245.29694; found [M + H]+ m/z 246.05816 (calcd m/z 246.05887). 
Synthesis of 3-(tert-butylethynyl)-1,2-benzisothiazole 1,1-dioxide (10-3) 
 In a dry flask was dissolved 405.9 mg (4.941 mmol) of 3,3-dimethylbutyne 
(SigmaAldrich) in 10 mL of dry THF.  The solution was stirred and cooled to –78 °C 
under a nitrogen atmosphere.  One equiv of 2.5 M n-BuLi solution in hexanes (1.98 mL) 
were added via syringe.  The reaction was left to stir for 4 h at 78 C.  A second 
solution of dry THF and 1.992 g (9.882 mmol, 2.000 equiv) of 3-chloro-1,2-
benzisothiazole 1,1-dioxide (9-1) was cooled to a temperature of –78 °C under a 
nitrogen atmosphere, and the lithiated alkyne solution was added dropwise via syringe 
to the benzisothiazole solution over 20 min.  After the addition was complete, the 
reaction was left to stir at –78 °C for 1 h, at which time it was quenched with satd aq 
NH4Cl at –78 °C.  The mixture was left to warm to room temperature whereupon the 
product was extracted with Et2O.  The mixture was then separated in a separatory 
funnel, and the organic layer was dried with anhyd MgSO4, vacuum filtered, and rotary 
evaporated.  The desired product was purified on silica gel chromatography by eluting 
with a 3:1 mixture of Et2O and hexane to purify the desired product to give 719.9 mg 
(58.99% yield). 1H NMR:  1.46 (9H, s, C(CH3)3), 7.727.78 (3H, m, ArH), 7.857.93 
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(1H, m, ArH); 13C NMR:  28.76 (C(CH3)3), 29.91 (C(CH3)3), 71.68 (CC), 118.76 (CC), 
122.26, 125.00, 131.44, 133.73, 133.92, 138.85 (Ar), 156.79 (C=N) DARTHRMS: Calcd 
for C13H13NO2S m/z 247.31282; found [M + H]
+ m/z 248.07567 (calcd m/z 248.07452). 
Synthesis of 3-(cyclopropylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1dioxide 
(16-1) 
In a dry flask, 0.9651 g (4.178 mmol) of 3-(cyclopropylethynyl)-1,2-benzisothiazole 1,1-
dioxide (10-1) was dissolved in 100% EtOH at room temperature.  While stirring, 2.326 
g (6.242 mmol, 1.494 equiv) of CeCl3•7H2O was added to the solution with stirring for 2 
h at room temperature. After 2 h, 0.2305 g (6.093 mmol, 1.458 equiv) of NaBH4 was 
added to the solution at room temperature with stirring for 3 h.  The reaction was 
worked up with DOWEX-50 in [H+] form and stirred for 1 h.  The resin was filtered off, 
and the EtOH was rotary evaporated off leaving a solid.  The solid was dissolved in 
DCM, and was washed with H2O (3  10 mL).  The organic layer was dried with anhyd 
MgSO4 and filtered.  The solvent was rotary evaporated, and the desired product was 
purified on silica gel chromatography by eluting with a 4:1 mixture of DCM and hexane 
to purify the desired product to give 0.5660 g (58.14% yield). 1H NMR:  0.690.72 (2H, 
m, CHCH2CH2), 0.780.83 (2H, m, CHCH2CH2), 1.231.30 (1H, m, CH2CHCH2), 4.99 
(1H, s, NH), 5.37 (1H, d, J = 5.5 Hz CHNH), 7.527.55 (2H, t, ArH), 7.637 (1H, t, J = 7.5 
Hz, ArH), 7.74 (1H, d, J = 8.0 Hz, ArH); 13C NMR:  -0.47 (CHCH2), 8.39 (CH2CH), 
49.02 (CHNH), 69.92 (CC), 90.57 (CC), 121.06, 124.91, 129.72, 133.45, 135.06, 138.37 
(Ar) DARTHRMS: Calcd for C12H11NO2S m/z 233.05105; found [M + H]
+ m/z 234.05850 
(calcd m/z 234.05887). 
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Synthesis of 3-(cyclobutylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide 
(16-2) 
In a dry flask, 117.2 mg (0.4763 mmol) of 3-(cyclobutylethynyl)-1,2-benzisothiazole 1,1-
dioxide (10-2) was dissolved in 100% EtOH at room temperature.  While stirring, 226.2 
mg (0.7145 mmol, 1.500 equiv) of CeCl3•7H2O was added to the solution, and the 
mixture was stirred for 2 h at room temperature. The reaction was then cooled to 0 C, 
and 37.3 mg (0.986 mmol, 2.07 equiv) of NaBH4 was added to the solution at 0 C, and 
the mixture was stirred for 30 min. The reaction was brought to room temperature and 
stirred for an additional 1 h, at the end of which time it was worked up with DOWEX-50 
in [H+] form and stirred for 1 h.  The resin was filtered off, and the EtOH was rotary 
evaporated off leaving a solid.  The solid was dissolved in DCM, and was washed with 
H2O (3  10 mL).  The organic layer was dried with anhyd MgSO4 and filtered.  The 
solvent was rotary evaporated, and the desired product was purified on silica gel 
chromatography by eluting with a 4:1 mixture of DCM to hexane to purify the desired 
product to give 87.3 mg (74.1% yield). 1H NMR:  1.821.97 (2H, m, CH2CH2CH2), 
2.012.14 (2H, m, CHCH2CH2), 2.162.30 (2H, m, CHCH2CH2), 3.04 (1H, quintet, J = 
8.5 Hz, CH2CHCH2), 4.97 (1H, s, CHNH), 5.44 (1H, s, CHNH), 7.507.56 (2H, m, ArH), 
7.65 (1H, t, J = 8.0 Hz, ArH), 7.74 (1H, d, J = 7.0, ArH); 13C NMR:  18.99 
(CH2CH2CH2), 24.44 (CH2CHCH2), 29.26 (CHCH2CH2), 29.28 (CHCH2CH2), 48.69 
(CHNH), 75.30 (CC), 90.94 (CC), 120.81, 124.76, 129.50, 133.27, 134.86, 138.25 (Ar); 
DARTHRMS: Calc for C13H15NO2S m/z 247.06670; found [M + H]
+ m/z 248.07540 
(calcd m/z 248.07452). 
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Synthesis of 3-(tert-butylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (16-
3) 
In a dry flask, 315.5 mg (1.277 mmol) of 3-(t-butylethynyl)-1,2-benzisothiazole 1,1-
dioxide (10-3) was dissolved in 100% EtOH at room temperature. While stirring, 713.9 
mg (1.916 mmol, 1.500 equiv) of CeCl37H2O was added to the solution, and the 
mixture was stirred for 2 h at room temperature. After 2 h, 72.5 mg (1.92 mmol, 1.50 
equiv) of NaBH4 was added to the solution at room temperature, and stirring continued 
for 3 h. The reaction was worked up with DOWEX-50 in [H+] form and stirred for 1 h. 
The resin was filtered off, and the EtOH was rotary evaporated off leaving a solid. The 
solid was dissolved in DCM and was washed with H2O (3  10 mL). The organic layer 
was dried with anhyd MgSO4 and filtered. The solvent was rotary evaporated, and the 
desired product was purified on silica gel chromatography by eluting with 3:1 DCM to 
petroleum ether to give the purified desired product at 238.5 mg (74.9% yield). 1H NMR: 
 1.22 (9H, s, C(CH3)3), 4.81 (1H, s, NH), 5.41 (1H, d, CHNH), 7.537.56 (2H, t, ArH), 
7.647.67 (1H, td, ArH), 7.75 (1H, d, ArH); 13C NMR:  27.59 (C(CH3)3), 30.46, 
(C(CH3)3), 48.86 (CHNH), 73.14, (CC), 95.77 (CC), 120.93, 124.78, 129.58, 133.33, 
135.24, 138.86 (Ar); DARTHRMS: Calc for C13H15NO2S m/z 249.08235; found [M + H]
+ 
m/z 250.08992 ( calcd m/z 250.09017). 
Synthesis of 3-(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-
dioxide (25-1) 
In a dry flask, 139.0 mg (0.5958 mmol) of 3-(cyclopropylethynyl)-2,3-dihydro-1,2-
benzisothiazole 1,1-dioxide (16-1) was dissolved in dry acetonitrile.  The temperature 
was brought to 0 C, and 581.0 mg (1.788 mmol, 3.001 equiv) of Cs2CO3 was added, 
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followed by dropwise addition of 0.19 mL (3.1 mmol, 5.1 equiv) of CH3I.  After 45 min at 
0 C, the ice bath was removed and the reaction was stirred at room temperature for 2 
h.  The solution was quenched with satd aq NH4Cl and extracted with EtOAc. The 
organic layer was washed with H2O (2  15 mL) and a solution of brine. The organic 
layer was separated, dried with anhyd MgSO4, and rotary evaporated. The desired 
product was purified on silica gel chromatography with an elution of 2:1 petroleum ether 
to EtOAc to give the desired product at 104.8 mg (71.15% yield).  1H NMR:  0.660.72 
(2H, m, CHCH2), 0.740.83 (2H, m, CHCH2), 1.221.31 (1H, m, CHCH2), 2.95 (3H, s, 
NCH3), 5.01 (1H, s, CHN), 7.527.77 (4H, m, ArH); 
13C NMR:  -0.61 (CHCH2), 8.51 
(CHCH2), 27.67 (NCH3), 54.37 (CHNCH3), 68.40 (CC), 91.44 (CC), 121.13, 124.72, 
129.66, 133.10, 134.02, 135.47 (Ar); DARTHRMS: Calcd for C13H13NO2S m/z 
247.31282; found [M + H]+ m/z 248.07506 (calcd m/z 248.07452). 
Synthesis of 3-(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-
dioxide (25-2) 
In a dry flask, 181.8 mg (0.7351 mmol) of 3-(cyclobutylethynyl)-2,3-dihydro-1,2-
benzisothiazole 1,1-dioxide (16-2) was dissolved in dry acetonitrile and brought to 0 C. 
Once at 0 C, 726.6 mg (3.041 equiv, 2.236 mmol) of Cs2CO3 was added, followed by 
dropwise addition of 0.23 mL (5.0, equiv, 3.7 mmol) of CH3I. After 45 min at 0 C, the 
ice bath was removed and the reaction stirred for 3 h. The solution was quenched with 
satd aq NH4Cl and extracted with EtOAc. The organic layer was washed with H2O (2  
15 mL) and a brine solution. The organic layer was dried with anhyd MgSO4, filtered, 
and rotary evaporated. The desired product was purified on silica gel chromatography 
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by eluting with 2:1 petroleum ether to EtOAc to give the desired product at 141.3 mg 
(73.56%). 1H NMR:  1.861.98 (2H, m, CH2), 2.082.16 (2H, m, CH2), 2.242.30 (2H, 
m, CH2), 2.98 (3H, s, NCH3), 3.033.09 (1H, m, CH2CHCH2), 5.08 (1H, s, NCH), 
7.537.58 (2H, m, ArH), 7.65 (1H, td,J = 5 Hz, J = 1.25, ArH), 7.78 (1H, d, J = 10 Hz, 
ArH); 13C NMR:  19.22 (CH2CH2CH2), 24.76 (CH2CHCH2), 27.71 (NCH3), 29.67 
(CHCH2CH2), 54.42 (NCH), 73.98 (CC), 91.92 (CC), 121.15, 124.73, 129.65, 133.10, 
134.05, 135.05 (Ar); DARTHRMS: Calcd for C14H15NO2S m/z 261.33940; found [M + 
H]+ m/z 262.09133 (calcd m/z 262.09017). 
 Synthesis of 3-(tert-butylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-
dioxide (25-3)  
In a dry flask, 238.6 mg (0.9570 mmol) of 3-(t-butylethynyl)-2,3-dihydro-1,2-
benzisothiazole 1,1-dioxide (16-3) was dissolved in dry acetonitrile.  To the mixture was 
added 460.1 mg (1.479 equiv, 1.416 mmol) of Cs2CO3 at room temperature and was 
stirred for 45 min.  After 45 min., 0.30 mL (5.0 equiv, 4.8 mmol) of CH3I was added to 
the solution dropwise at room temperature, and the mixture was stirred for 1 h.  The 
solution was quenched with H2O and rotary evaporated on the high vacuum.  The 
remaining oil was dissolved in DCM and washed with H2O (2  5 mL) and dried with 
anhyd MgSO4.  The drying agent was filtered off, and the solvent was rotary evaporated 
off leaving a yellow oil.  The desired product was purified with an elution of 2:1.5:0.1 
mixture of hexanes to EtOAc to CHCl3 on silica gel chromatography to give 118.5 mg 
(47.0% yield) 1H NMR:  1.22 (9H, s, C(CH3)3), 2.94 (3H, s, NCH3), 5.03 (1H, s, 
CHNCH3), 7.517.76 (4H, m, ArH); 
13C NMR:  27.52 (C(CH3)3, 27.63 (NCH3), 30.74 
(C(CH3)3), 54.35 (CHNCH3), 71.74 (CC), 96.48 (CC), 121.03, 124.64, 129.61, 133.10, 
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134.02, 135.69 (Ar); DARTHRMS: Calcd for C14H17NO2S m/z 263.09800; found [M + 
H]+ m/z 264.10690 (calcd m/z 264.10582). 
Synthesis of 3-(m-vinylphenyl)-1,2-benzisothiazole 1,1-dioxide (26-1) 
In an oven dried 2-necked flask, addition funnel, and reflux column was added 100.8 mg 
(1.000 equiv, 4.147 mmol) Mg0 turnings, and the apparatus was purged with nitrogen for 
20 min. After 20 min. of purging, dry THF was added to the flask, and the mixture was 
purged for 20 min and stirred vigorously. After bringing the mixture to reflux, a solution 
of 0.7595 g (4.149 mmol) of 3-bromostyrene (Matrix Scientific) in dry THF was added 
dropwise to the solution. The reaction was stirred at reflux until the solution turned a 
yellow-brown color, and the magnesium turnings no longer remained. In a oven-dried 
round-bottom flask was dissolved 722.3 mg (0.9503 equiv, 3.943mmol) of saccharin in 
dry THF, and the solution was purged with nitrogen and brought to 0 C. At 0 C, 3.95 
mL of a 1.0 M solution of phenyl magnesium bromide (SigmaAldrich) (0.952 equiv, 
3.95 mmol) was added dropwise at 0 C to the saccharin solution to deprotonate the 
saccharin. After stirring for some time at 0 C, the (3-vinylphenyl)magnesium bromide 
solution was added dropwise to the solution of deprotonated saccharin at 0 C with 
warming to room temperature. The solution was allowed to stir overnight under nitrogen. 
The reaction was quenched with ice water and then brought to pH 1 with 1 N HCl. The 
organic compound was extracted with Et2O, and washed with a 10% NaHCO3 solution 
to remove unreacted saccharin. The organic layer was dried with anhyd MgSO4, filtered, 
and rotary evaporated to produce a yellow solid. The desired product was purified on 
silica gel chromatography with an elution of 2:1 mixture of petroleum ether to EtOAc to 
give 660.4 mg (62.19% yield). 1H NMR:  5.42 (1H, d, J = 10 Hz CH=CH2), 5.89 (1H, d, 
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J = 20 Hz, CH=CH2), 6.81 (1H, quartet, J = 10 Hz, J = 20 Hz, CH=CH2), 7.58 (1H, t, J = 
10 Hz, ArH), 7.72-7.85 (4H, m, ArH), 7.89-7.91 (1H, m, ArH), 7.99 (1H, t, J = 5.0 Hz, 
ArH), 8.02-8.04 (1H, m, ArH); 13C NMR:  116.23 (CH=CH2), 123.10 (Ar), 126.51 (Ar), 
127.18 (Ar), 128.54 (Ar), 129.36 (Ar), 130.54 (Ar), 130.75 (Ar), 130.89 (Ar), 133.42 (Ar), 
133.66 (Ar), 135.43 (CH=CH2), 138.85 (Ar), 141.10 (Ar), 170.99 (C=N). DARTHRMS: 
Calcd for C15H12NO2S m/z 269.31834; [M +H]
+ m/z 270.06044 (calcd m/z 270.05887). 
Synthesis of (S)-3-(m-vinylphenyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide (26-
2) 
In an oven-dried flask, 660.4 mg (2.452 mmol) of 3-(m-vinylphenyl)-1,2-benzisothiazole 
1,1-dioxide (26-1) was added to dry DCM. With a ratio of 200:1 imine to catalyst, 8.9 mg 
(0.014 mmol) of pre-formed Cp*RhCl[(1R,2R)-p-TsNCH(C6H5)CH(C6H5)NH2] was 
added, and the mixture was stirred at room temperature under nitrogen. At this time, 0.4 
mL of an azeotropic mixture of 5:2 formic acidtriethylamine was added, and the 
reaction was stirred for 30 min. After evidence that the substrate had disappeared by 
TLC, the reaction was worked-up with 1 M NaHCO3 and extracted with DCM. The 
combined organic phase was washed with brine, dried over MgSO4, and concentrated 
to give a crude product. The desired product was purified on silica gel chromatography 




+119° (c=0.1, CHCl3); 
1H NMR:  5.05 (1H, s, NH), 5.28 (1H, d, J = 10 Hz, CH=CH2), 
5.71 (1H, d, J = 5 Hz, CHNH), 5.76 (1H, d, J = 20 Hz, CH=CH2), 6.68 (1H, quartet, J = 
10 Hz, J = 20 Hz, CH=CH2), 7.13-7.83 (8H, m, ArH); 
13C NMR:  61.28 (CHNH), 115.12 
(CH=CH2), 121.15 (CH=CH2), 125.33, 125.40, 126.76, 126.87, 129.47, 129.51, 133.33, 
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134.78, 136.01, 138.64, 139.00, 139.65 (Ar); Calcd for C15H13NO2S m/z 271.06670; 
found [M + H]+ m/z 272.07352 (calcd m/z 272.07452). 
Synthesis of (S)-3-(m-vinylphenyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-
dioxide (26-3) 
To a solution of 620.0 mg (2.285 mmol) (S)-3-(m-vinylphenyl)-2,3-dihydro-1,2-
benzisothiazole 1,1-dioxide (26-2) in dry acetonitrile was added 1.4800 g (1.9929 equiv, 
4.5538 mmol) of Cs2CO3. The mixture stirred for 1 h, at which time 0.29 mL (2.1 equiv, 
4.7 mmol) of CH3I were added, and the mixture stirred until completion of the reaction 
as shown by TLC. The reaction was quenched with water, and the mixture was rotary 
evaporated under high vacuum. The product was taken up in DCM, and washed with 
water (3  15 mL) followed by a brine wash. The organic phase was dried with anhyd 
MgSO4, and rotary evaporated. The desired product was purified on silica gel 




 +138° (c=0.1, CHCl3); 
1H NMR:  2.78 (3H, s, NCH3), 5.18 (1H, s, CHN), 5.29 
(1H, d, J = 10 Hz, CH=CH2), 5.77 (1H, d, J = 20 Hz, CH=CH2), 6.70 (1H, quartet, J = 10 
Hz, J = 20 Hz, CH=CH2), 7.03-7.86 (8H, m, ArH); 
13C NMR:  27.51 (NCH3), 66.94 
(CHN), 115.01 (CH=CH2), 121.12 (CH=CH2), 124.98, 125.91, 126.84, 127.50, 129.33, 
129.40, 132.97, 134.06, 136.07, 136.99, 138.24, 138.58 (Ar); DARTHRMS: Calcd for 
C16H15NO2S m/z 285.36080; found [M + H]
+ m/z 286.09156 (calcd m/z 286.09017). 
Synthesis of (S)-3-(m-cyclopropylphenyl)-2,3-dihydro-2-methyl-1,2-
benzisothiazole 1,1-dioxide (26-4) 
In an oven-dried flask was dissolved 180.6 mg (2.002 equiv, 0.9812 mmol) of 
pentafluorophenol in dry dichlorohmethane under nitrogen. The solution is brought to 
 106 
40 C, and 0.98 mL of 1 M Et2Zn (2.0 equiv, 0.98 mmol) is added to the solution to stir 
for 15 min. After 15 min. has passed, 0.10 mL (2.5 equiv, 1,2 mmol) of CH2I2 is added to 
the solution to continue stirring for 15 min. at 40 C. After 15 min has passed, a 
solution of 140.0 mg of sultam 26-3 (1.000 equiv, 0.4901 mmol) in dry dichloromethane 
is added, and the cold bath is removed to allow the reaction to warm to room 
temperature. The reaction was stirred for 18 h. The reaction was washed with 10% aq 
HCl (2  25 mL), satd aq NaHCO3 (2  25 mL), satd aq Na2SO3 (25 mL), and satd aq 
NaCl (25 mL). The organic layer was dried over MgSO4, filtered, and rotary evaporated.
 
The product was purified on silica gel chromatography with an elution of 2:1 hexanes to 
EtOAc to give 78.1 mg (53.2% yield). []
  
 
 +117° (c=0.1, CHCl3); 
 1H NMR  0.68 (2H, m, 
CHCH2CH2), 0.97 (2H, m, CHCH2CH2), 1.88 (1H, m, CHCH2CH2), 2.76 (3H, s, NCH3), 
5.13 (1H, s, CHN), 7.01-7.84 (8H, m, ArH); 13C NMR  9.57 (CHCH2CH2), 9.62 
(CHCH2CH2), 15.36 (CH2CHCH2), 27.42 (NCH3), 67.04 (CHNCH3), 121.06, 124.99, 
125.20, 125.67, 125.85, 129.07, 129.25, 132.92, 134.01, 136.09, 138.44, 145.31 (Ar); 
DARTHRMS: Calcd for C17H17NO2S m/z 299.38738; found [M + H]
+ m/z 300.10610 
(calcd m/z 300.10582). 
Synthesis of 3,3-bis(cyclopropylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-
dioxide (12-1) 
In a dry flask was dissolved 301.0 mg (4.554 mmol) of ethynylcyclopropane in 10 mL of 
dry THF.  The solution was stirred and cooled to –78 °C under a nitrogen atmosphere. 
At this time, 1.90 mL (4.56 mmol, 1.00 equiv) of 2.4 M n-BuLi solution in hexanes were 
added via syringe.  The reaction was left to stir for 4 h at 78 C.  A second solution of 
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dry THF and 457.7 mg (0.4985 equiv, 2.270 mmol) of 3-chloro-1,2-benzisothiazole 1,1-
dioxide (9-1) was added dropwise to the solution of lithiated ethynylcyclopropane at –78 
°C.  The mixture was allowed to warm to 10 °C over an hour, and the reaction was 
worked up with satd aq NH4Cl and allowed to warm up to room temperature.  The solid 
was filtered off, and the two layers were separated. An Et2O extraction was performed 
on the aqueous layer, and combined with the organic layer.  The organic layer was 
dried with anhyd MgSO4, which was filtered off, and the solvent was rotary evaporated 
off leaving a solid.  The desired product was purified on silica gel chromatography by 
eluting with a 3:1 mixture of Et2O to hexane to purify the product to give 472.3 mg 
(69.53% yield). 1H NMR:  0.62-0.78 (8H, m, CHCH2CH2), 1.17-1.26 (2H, m, 
CH2CHCH2), 5.17 (1H, s, NH), 7.44-7.57 (1H, m, ArH), 7.64-7.70 (3H, m, ArH); 
13C 
NMR:  -0.74 (CH2CHCH2), 8.35 (CHCH2CH2), 52.29 (CN), 72.11 (CC), 88.59 (CC), 
120.95, 124.90, 134.04, 133.29, 133.99, 140.73 (Ar); DARTHRMS: Calcd for 
C17H15NO2S m/z 297.37150; found [M + H]
+ m/z 298.08973 (calcd m/z 298.09017). 
Synthesis of 3,3-bis(cyclobutylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-
dioxide (12-2) 
In a dry flask was dissolved 3.7623 g (0.032270 mol) of 6-chlorohexyne in dry THF. The 
mixture was brought to 78 C and 29.8 mL (0.0685 mol, 2.12 equiv) of 2.3 M n-BuLi 
was slowly injected for 20 min, whereupon the mixture was kept at 78 C for at least 20 
min afterwards. This solution was warmed to room temperature overnight, quenched 
with NH4Cl, extracted with Et2O, dried with anhyd MgSO4, and the Et2O was distilled of 
to leave the product in THF. 4 Å Molecular sieves were added to the solution, and it was 
cooled to 78 C. At this time, 14.0 mL (0.0323 mol, 1.00 equiv) of 2.3 M n-BuLi was 
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added to the solution dropwise, and the mixture was stirred for 4 h at 78 C. A solution 
of 3.2482 g (0.016110 mol, 0.50000 equiv) of 3-chloro-1,2-benzisothiazole 1,1-dioxide 
(9-1) in dry THF was added dropwise to the solution of lithiated ethynylcyclobutane, and 
the mixture was allowed to warm to 10 C over 1 h. The reaction mixture was worked up 
with satd aq NH4Cl and allowed to warm up to room temperature.  The solid was filtered 
off, and the two layers were separated. An Et2O extraction was performed on the 
aqueous layer, and combined with the organic layer.  The organic layer was dried with 
anhyd MgSO4, which was filtered off, and the solvent was rotary evaporated off leaving 
a solid.  The desired product was purified on silica gel chromatography with an elution 
of a 2:1 petroleum ether and EtOAc to purify the desired product at 0.7764 g (14.81% 
yield). 
1H NMR:  1.79-1.93 (4H, m, CH2CH2CH2), 2.03-2.15 (4H, m, CHCH2CH2), 2.15-
2.24 (4H, m, CHCH2CH2) 2.98-3.05 (2H, quintet, CH2CHCH2), 5.06 (1H, s, CNH), 7.53-
7.57 (1H, m, ArH), 7.66-7.70 (2H, m, ArH), 7.71-7.73 (1H, d, ArH); 13C NMR:  19.15 
(CH2CH2CH2), 24.67 (CH2CHCH2), 29.30 (CHCH2CH2), 29.31 (CHCH2CH2), 52.41 
(CNH), 78.18 (CC), 89.13 (CC), 120.95, 124.98, 130.08, 133.46, 134.00, 140.97 (Ar). 
DARTHRMS: Calcd for C19H19NO2S m/z 325.11365; found [M + H]
+ m/z 326.12147 
(calcd m/z 326.12124). 
Synthesis of 3,3-bis(tert-butylethynyl)-2,3-dihydro-1,2-benzisothiazole 1,1-dioxide 
(12-3) 
In a dry flask was dissolved 473.2 mg (5.761 mmol) of 3,3-dimethylbutyne in 10 mL of 
dry THF.  The solution was stirred and cooled to –78 °C under a nitrogen atmosphere.  
At 78 C, 2.51 mL (1.00 equiv, 5.77 mmol) 2.3 M n-BuLi solution in hexanes were 
added via syringe.  The reaction was left to stir for 4 h while at 78 C.  A second 
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solution of dry THF and 580.8 mg (0.5000 equiv, 2.881 mmol of 3-chloro-1,2-
benzisothiazole 1,1-dioxide (9-1) was added dropwise to the solution of lithiated 3,3-
dimethylbutyne at –78 °C.  The reaction mixture was allowed to warm to 10 °C over 1 h, 
and the reaction was worked up with satd aq NH4Cl and allowed to warm up to room 
temperature.  The solid was filtered off, and the two layers were separated. An Et2O 
extraction was performed on the aqueous layer, and combined with the organic layer.  
The organic layer was dried with anhyd MgSO4, which was filtered off, and the solvent 
was rotary evaporated off leaving a solid.  The desired product was purified on silica gel 
chromatography by eluting with a 2:1 mixture of petroleum ether to EtOAc to purify the 
product to give 837.1 mg 88.21% yield. 1H NMR:  1.18 (18H, s, C(CH3)3), 5.00 (1H, s, 
NH), 7.53-7-72 (4H, m, ArH); 13C NMR:  27.37 (C(CH3)3, 30.36 (C(CH3)3), 52.21 
(CNH), 76.49 (CC), 93.43 (CC), 120.85, 124.76, 129.93, 133.47, 133.90, 141.41 (Ar); 
DARTHRMS: Calcd for C19H23NO2S m/z 329.14495; found [M + H]
+ m/z 330.15426 
(calcd m/z 330.15277). 
Synthesis of 3,3-bis(cyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 
1,1-dioxide (25-4) 
In a dry flask was dissolved 856.3 mg (2.880 mmol) of sultam 12-1 in dry CH3CN.  Once 
dissolved, the mixture was brought to 0 C, whereupon 2.7962 g (2.987 equiv, 8.604 
mmol) of Cs2CO3 was added to the solution, followed by dropwise addition of 0.90 mL 
(5.0 equiv, 14 mmol) of CH3I. The reaction was stirred at 0 C for 45 min, and the ice 
bath was removed to warm the mixture to room temperature for 3 h. The mixture was 
quenched with NH4Cl and extracted with EtOAc. The organic layer was washed with 
H2O (2  15 mL) and a wash of brine.  The organic layer was dried with anhyd MgSO4 
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and filtered.  The organic solvent was rotary evaporated, and the product was purified 
on silica gel chromatography with an elution of 2:1 petroleum ether to EtOAc to give 
845.7 mg (94.30 % yield). 1H NMR:  0.61-0.69 (4H, m, CH2CHCH2), 0.72-0.78 (4H, m, 
CH2CHCH2), 1.20-1.26 (2H, m, CH2CHCH2), 2.93, (3H, s, NCH3), 7.52, (1H, t, ArH), 
7.62-7.71 (3H, m, ArH); 13C NMR:  -0.59 (CH2CHCH2), 8.48 (CH2CHCH2), 8.52 
(CH2CHCH2), 25.02 (NCH3) 56.32 (CNCH3), 70.20 (CC), 89.70 (CC), 120.94, 124.66, 
129.93, 132.70, 133.53, 138.66 (Ar); DARTHRMS: Calcd for C18H17NO2S m/z 
311.39808; found [M + H]+ m/z 312.10698   (calcd m/z 312.10582). 
Synthesis of 3,3-bis(cyclobutylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 
1,1-dioxide (25-5) 
In a dry flask was dissolved 89.4 mg (0.275 mmol) of sultam 12-2 in dry CH3CN, and the 
solution was brought to 0 C. At 0 C, 134.4 mg of Cs2CO3 (1.503 equiv, 0.4135mmol) 
was added, followed by the dropwise addition of 0.10 mL (5.8 equiv, 1.6 mmol) of CH3I. 
After 45 min of stirring at 0 C, the ice bath was removed, and the mixture was stirred 
for 3 h at room temperature. The reaction was quenched with satd aq NH4Cl and 
washed with EtOAc. The organic layer was washed with H2O (2  15 mL) and a brine 
solution. The organic layer was dried with anhyd MgSO4 and filtered.  The organic 
solvent was rotary evaporated, and the product was purified on silica gel 
chromatography with an elution of 2:1 hexanes to EtOAc to give the desired product at 
70.4 mg (75.4% yield).  1H NMR:  1.84-1.97 (4H, m, CH2CH2CH2), 2.07-2.16 (4H, m, 
CHCH2CH2), 2.22-2.28 (4H, m, CHCH2CH2), 3.01 (3H, m, NCH3), 3.04 (2H, quintet, J = 
9.0 Hz CH2CHCH2), 7.57 (1H, t, J = 7.5 Hz, ArH), 7.68 (1H, t, J = 7.5 Hz, ArH), 7.74 
(1H, d, J = 10.0 Hz, ArH), 7.78 (1H, d, J = 10.0 Hz, ArH); 13C NMR:  19.18 
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(CH2CH2CH2), 24.74 (CH2CHCH2), 25.08 (CNCH3), 29.52 (CHCH2CH2), 56.47 
(CNCH3), 75.98 (CC), 90.07 (CC), 121.06, 124.69, 129.85, 132.82, 133.46, 138.93 (Ar) 
DARTHRMS: Calcd for C20H21NO2S m/z 339.12930; found [M + H]
+ m/z 340.13720   
(calcd m/z 340.13712). 
Synthesis of 3,3-bis(tert-butylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 
1,1-dioxide (25-6) 
In a dry flask was dissolved 837.1 mg (2.541 mmol) of sultam 12-3 in dry CH3CN.  Once 
dissolved, the solution was brought to 0 C, and  2.4916 g (3.0171, 7.6665 mmol) of 
Cs2CO3 was added to the solution, followed by the dropwise addition of 0.80 mL (5.1 
equiv, 13 mmol) of CH3I to the solution. The mixture was stirred for 45 min at 0 C, and 
the ice bath was removed allowing the reaction to warm to room temperature for 3 h. 
The reaction was quenched with satd aq NH4Cl, and the mixture was extracted with 
EtOAc. The organic layer was washed with H2O (2  15 mL) and then a brine solution.  
The organic layer was separated, dried with anhyd MgSO4, and filtered.  The organic 
solvent was rotary evaporated, and the compound was purified on silica gel 
chromatography with an elution of 4:1 petroleum ether to EtOAc to give 749.0 mg 
(85.82% yield). 1H NMR:  0.61-0.71 (4H, m, CH2CHCH2), 0.72-0.79 (4H, m, 
CH2CHCH2), 1.20-1.26 (2H, m, CH2CHCH2), 2.93 (3H, s, NCH3), 7.52 (1H, t, ArH), 7.62-
7.71 (3H, m, ArH); 13C NMR:  -0.59 (CH2CHCH2), 8.62 (CH2CHCH2), 25.00 (NCH3), 
56.27 (CNCH3), 70.30 (CC), 89.74 (CC), 121.05, 124.53, 129.78, 132.41, 133.49, 
138.75 (Ar); DARTHRMS: Calcd for C20H25NO2S m/z 343.48300; found [M + H]
+ m/z 
344.17032   (calcd m/z 344.16842). 
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5:2 Formic acid: triethylamine azeotrope 
A distillation apparatus was set up with a Vigreux column (15 cm) between the round-
bottom flask and the distilling head, and a water condenser leading to a bent vacuum 
adapter with a bent dropper attached to a distillation cow.  An approximate ratio of 5:2 
molar mixture of 98% formic acid and triethylamine were poured into the round-bottom 
flask with triethylamine being poured first.  The round-bottom flask was placed in a sand 
bath that was brought to approximately 200 °C.  The first fraction to come off was 
triethylamine at 88 °C, followed by formic acid at 100.8 °C.  The thermometer for some 
time showed a distillate at approximately 110 °C. Once this distillate was collected, the 
air condenser was removed, placing the still head directly on the round-bottom flask.  As 
the temperature rose up to 190 °C, these fractions were collected separately.  Once 190 
°C was reached, the distillation cow was turned so that a clean collector would collect 
the azeotrope.  The azeotrope was collected until either a change in temperature or 
before all liquid was distilled to prevent distilling to dry.  An NMR spectrum was 
performed on the azeotrope to confirm the 5:2 ratio.  The formyl H in formic acid has a 
shift at 8.25 ppm, and the triethylamine has the 3 CH2 groups with a shift at 3.0 ppm, 
and the 3 CH3 groups with a shift at 1.2 ppm.  The integrations on these peaks were 
normalized so that the methyl groups integrated to 18.00, resulting in the CH2 groups 
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